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ABSTRACT
Neurofibromatosis 2 (NF2) is an autosomal dominant disorder manifested by the
formation of multiple benign tumors of the nervous system. Affected individuals typically
develop bilateral vestibular schwannomas which lead to deafness and balance disorders.
The syndrome is caused by inactivation of the NF2 tumor suppressor gene, and mutation
or loss of the NF2 product, merlin, is sufficient for tumorigenesis in both hereditary and
sporadic NF2-associated tumors.
Merlin belongs to the band 4.1 superfamily of cytoskeletal proteins, which also contain
the related ezrin, radixin, and moesin (ERM) proteins. The ERM members provide a link
between the cell cytoskeleton and membrane by connecting membrane-associated
proteins to actin filaments. By stabilizing complexes in the cell cortex, the ERMs modulate
morphology, growth, and migration of cells. Despite their structural homology,
overlapping subcellular distribution, direct molecular association, and partial overlap of
molecular interactions, merlin and ezrin exert opposite effects on cell proliferation. Merlin
suppresses cell proliferation, whereas ezrin expression is linked to oncogenic activity. We
hypothesized that the regions which differ between the proteins might explain merlin’s
specificity as a tumor suppressor. We therefore analyzed the regions, which are most
diverse between merlin and ezrin; the N-terminal tail and the C-terminus. To determine
the properties of the C-terminal region, we studied the two most predominant merlin
isoforms together with truncation variants similar to those found in patients. We also
focused on the evolutionally conserved C-terminal residues, E545-E547, that harbor
disease causing mutations in its corresponding DNA sequence.
In addition to inhibiting cell proliferation, merlin regulates cytoskeletal organization.
The morphogenic properties of merlin may play a role in tumor suppression, since
patient-derived tumor cells demonstrate cytoskeletal abnormalities. We analyzed the
mechanisms of merlin-induced extension formation and determined that the C-terminal
region of amino acids 538-568 is particularly important for the morphogenic activity. We
also characterized the role of C-terminal merlin residues in the regulation of proliferation,
phosphorylation, and intramolecular associations. In contrast to previous reports, we
demonstrated that both merlin isoforms are able to suppress cell proliferation, whereas C-
terminally mutated merlin constructs showed reduced growth inhibition.
Phosphorylation serves as a mechanism to regulate the tumor suppressive activity of
merlin. The C-terminal serine 518 is phosphorylated in response to both p21-activated
kinase (PAK) and protein kinase A (PKA), which inactivates the growth inhibitory function
of merlin. However, at least three differentially phosphorylated forms of the protein exist.
In this study we demonstrated that also the N-terminus of merlin is phosphorylated by
AGC kinases, and that both PKA and Akt phosphorylate merlin at serine 10 (S10). We
evaluated the impact of this N-terminal tail phosphorylation, and showed that the
phosphorylation state of S10 is an important regulator of merlin’s ability to modulate
cytoskeletal organization but also regulates the stability of the protein.
In summary, this study describes the functional effect of merlin specific regions. We
demonstrate that both S10 in the N-terminal tail and residues E545-E547 in the C-
terminus are essential for merlin activity and function.
Review of the literature
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REVIEW OF THE LITERATURE
1. Cancer
Cancer, the uncontrolled proliferation of cells, is caused by genetic changes. Multiple
genetic alterations accumulate progressively during transformation when cells evolve
from normal phenotypes via premalignant states towards malignant cancer. It has been
estimated that between four and seven rate-limiting mutations are required for cancer cell
transformation1,2. The premalignant mutated cells are converted into a neoplastic clone
when the genetic alterations are transferred from the cancer cell to its progeny cells
constituting a primary tumor3.
Cancers can be divided into familial and sporadic according to inherited or
environmental causing factors. The sporadic cancers which occur spontaneously and
result from acquired mutations, account for approximately 90% of all malignancies.
Although many risk factors for cancer are recognized, no single factor increases the
chance of malignancy as much as a genetic predisposition4. However, regardless of the
underlying causing factor, tumor development in both sporadic and inherited cancers
shares the same basic mechanism.
1.1. Tumorigenesis
More than 100 different forms of cancer exist, each with several subtypes. In spite of the
large number of distinct tumors, they all evolve similarly. The transformation of normal
cells into tumors; tumorigenesis, is a multistep process during which cells are genetically
altered to confer a growth advantage. Malignant transformation involves six essential
physiological changes: self-sufficiency in growth signals, insensitivity to growth-inhibitory
signals, resistance to apoptosis, limitless replicative potential, induced angiogenesis, and
activation of tissue invasion and metastasis5. Also genomic instability, inflammation,
changed energy metabolism and the ability to evade the immune system are typical
features of cancer progression6. These biological capabilities, acquired through changes
in cancer cell genomes, are shared by most types of human tumors5.
The dependence on environmental stimulation is altered in malignant cells. Many
antiproliferative signals maintain cellular quiescence within normal tissue by restricting the
rate of cell division. Cancer cells are able to evade these signals by becoming insensitive
to them, leading to their enhanced proliferation. Tumor cells also show reduced
dependence on exogenous growth stimulation compared to normal cells, which are not
able to proliferate in the absence of growth promoting signals. Transformed cells become
sensitive to low levels of growth factors that would not normally trigger their proliferation
by either overexpressing growth receptors or by favoring the receptors that transmit
progrowth signals5.
Most cells carry a cell-autonomous program that restricts their multiplication, but this
system is disrupted in cancer cells, which require limitless replicative potential during their
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transformation into malignant tumors. The ability to multiply without limit, immortalization,
is achieved by avoiding replicative senescence. This capability for unlimited proliferation
is usually acquired by telomere maintenance5, and 85-90% of cancer cells succeed in
sustaining their telomeres by upregulating the expression of telomerase, a telomere
extending enzyme7. Normal cells stop proliferating and enter into a quiescent state upon
cell-cell contact, but cancer cells show loss of contact inhibition leading to tumor
formation8. However, neoplastic cell populations continue multiplying not only because of
their higher rate of proliferation, but also due to decreased apoptosis that normally
controls proliferation by eliminating excess cells. Tumor cells become resistant to cell
death through inactivation of the apoptotic cascade, most commonly occurring by loss of
the p53 tumor suppressor gene5. The p53 protein functions as a DNA damage sensor
that normally induces the apoptotic machinery, but the protein is inactivated in about 50%
of human cancers9. As a consequence of both increased replicative potential and
reduced apoptosis, transformed cells are able to expand to a size that constitutes a
tumor.
Tumor growth also requires angiogenesis, a carefully regulated process by which
existing quiescent vasculature is induced to grow new capillary blood vessels. A
developing tumor needs to obtain the ability to stimulate angiogenesis, as the oxygen and
nutrients supplied by the vasculature are necessary for cell survival. Thus, although
angiogenesis does not initiate malignancy, it promotes tumor progression and metastasis.
Different tumor types use distinct molecular strategies to activate angiogenesis, but many
of them secrete angiogenic growth factors, such as vascular endothelial growth factor
(VEGF)10.
Benign tumors evolve to cancer when they obtain the ability to spread. The capability
for invasion and metastasis enables malignant cells to break away from the tumor and
migrate to distant organs. Cancer metastasis is a multistep process involving cell
detachment from the primary tumor and invasion into the surrounding tissue,
intravasation into the vascular or lymphatic system, spreading through the circulation, and
extravasation and colonization in the target organ. Metastasis is mediated by different
classes of genes affecting initiation, progression, and cancer cell virulence11. It is
enhanced by alterations in proteins that normally keep the cells of a tissue adherent or
are involved in tethering cells to their surroundings. Several classes of proteins, such as
cell-cell adhesion molecules (CAMs), integrins, and enzymes that cleave the extracellular
matrix (ECM) are central to the acquisition of invasiveness and metastatic ability and the
expression of these proteins is often altered in cancer cells5.
1.2. Cancer genes
Almost 300 cancer associated genes have been identified, meaning that mutations in
more than 1% of our genes contribute to oncogenesis12. Cancer genes are grouped into
two broad classes; oncogenes and tumor suppressor genes. Tumorigenesis is induced
by either activation of proto-oncogenes or by loss of tumor suppressor genes, but
mutations in both these groups of genes have similar effects; increasing cell proliferation,
differentiation, and survival.
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1.2.1. Oncogenes
The genes with the potential to cause cancer by activating, gain-of-function mutations are
called oncogenes. Individuals carrying activated oncogenes as a result of chromosomal
translocations, gene amplifications, or mutations are highly tumor prone. Oncogenes are
tumor-inducing constitutively active converted forms of normal proto-oncogenes. More
than 100 proto-oncogenes have been identified, and many of them, such as Ras (rat
sarcoma), Myc (myelocytomatosis oncogene cellular homolog), ERK (extracellular signal-
regulated kinase), and EGFR (epidermal growth factor receptor), encode proteins that are
involved in regulating cell proliferation and differentiation. The mutations generally involve
only one of the oncogene alleles, which typically have a dominant effect on the cell, and
most cancer-causing oncogene mutations are acquired, not inherited13,14.
Oncogenes are involved in various signal transduction pathways, and alterations in
these genes can lead to continuous signaling. Overactivating oncogene mutations are
growth promoting by stimulating proliferation also in the absence of growth signals,
thereby predisposing the cell to malignancy. Targeted cancer therapy takes advantage of
the deregulated signaling in the tumor. Protein tyrosine kinases (PTKs) are the largest
group of dominant oncogenes comprising about 0.3% of all genes, and somatic mutations
in these genes cause a significant fraction of human cancers. Inhibition of oncogenic
PTKs is often enough to slow tumor progression, and therefore specific PTK inhibitors
have been developed. By analyzing signaling pathway activation in individual cancers,
the growth inducing event of the tumor can be determined and used for drug selection,
allowing for more personalized medicine15,16.
1.2.2. Tumor suppressors
Genes with inactivating, loss-of-function mutations generating the cancer risk are tumor
suppressor genes17. These genes are protective genes whose protein products normally
limit tumor growth. When a tumor suppressor gene is mutated leading to loss,
inactivation, or reduction of its function, its growth inhibitory activity is decreased and the
cell can progress towards malignancy18. More than 30 tumor suppressors have been
identified19, and they regulate a wide range of cellular activities, including proliferation and
cell cycle control, response to genetic damage, protein turnover, mitogenic signaling, cell
differentiation, migration, apoptosis, and angiogenesis. Tumor suppressors can also
prevent the formation of harmful mutations that could otherwise provide the cells with
further genetic alterations20.
According to Knudson’s two-hit model, two independent genetic events are required
for tumor suppressor gene inactivation. Both alleles of these genes must be affected
before an effect is manifested, as the presence of one functional allele is usually enough
for the cancer-preventing function. Prototypic mutant tumor suppressor genes are
therefore recessive. In hereditary cancers one of the mutations is passed through the
germline and the second hit is spontaneously formed, whereas in sporadic tumors two
somatic mutations inactivate both copies of the tumor suppressor gene, thus promoting
tumor growth21. Although most tumor suppressors follow this two-hit inactivation, also
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exceptions exist. Some tumor suppressors are haploinsufficient, meaning that functional
loss of only one allele is sufficient to confer a growth advantage that induces
malignancy22. Tumor suppressors can also be inactivated without genetic alterations by
epigenetic silencing such as through methylation23.
Tumor suppressors are divided into gatekeepers, caretakers, and landscapers
depending on their function24. Gatekeepers act directly to prevent tumor growth by
inhibiting cell proliferation or by promoting apoptosis, and function for example as
transcription factors. Both alleles of a gatekeeper gene must be mutated for tumor
development and inactivation of these genes is the rate-limiting event in tumorigenesis.
Individuals with a hereditary mutation in a gatekeeper gene have more than a 1000-fold
greater risk of developing tumors than the general population. A tumor suppressor gene
that functions as a caretaker operates indirectly to suppress growth by protecting the
genome. Caretaker genes are involved in DNA-repair and genome integrity, and
mutations in these genes lead to genomic instability, but not directly to cancer. However,
caretaker mutations increase the rate by which mutations accumulate in other genes,
thereby raising the probability that some gatekeeper function will be lost. Mutations in
caretaker genes increase the risk of developing cancer by 5-50-fold25. Landscaper tumor
suppressors do not directly affect cellular growth, but they act by modulating the
microenvironment of the tumor cells. These genes regulate ECM proteins, surface
receptors, adhesion proteins, or secreted growth factors. Defects in landscapers generate
an abnormal stromal environment that allows for the neoplastic transformation24,26.
1.3. Inherited Cancer Syndromes
A cancer syndrome is a genetic predisposition to develop cancer. Although cancer is a
common disease, only 5-10% of all malignancies arise as a result of inherited gene
mutations27. Germline mutations in cancer genes can be transferred from one generation
to the next and result in a varying increased risk to develop cancer during lifetime,
depending on the mutation and on environmental factors4,28. Individuals with a definite
cancer family history are predicted to have a two-fold risk of cancer compared to the
general population, whereas those who carry a germline mutation in a cancer gene may
have more than an 80% lifetime risk of forming a specific cancer29. However, less than
0.3% of the population are carriers of a genetic mutation that has a strong effect on the
cancer risk30.
Over 200 hereditary cancer syndromes have been identified, but many of these
conditions are rare31. The majority of them are autosomal dominantly inherited and highly
penetrant. Both tumor suppressors and oncogenes cause cancer susceptibility if inherited
in a mutated state, but inactivating mutations in tumor suppressor genes are more
common in inherited cancer predispositions than mutations in oncogenes28, presumably
because the loss-of-function mutation of a tumor suppressor is masked by the remaining
normal allele during development, whereas gain-of-function mutations could be lethal32.
In hereditary cancers, the first mutation in a cancer gene is inherited and recessive,
whereas the second hit in the remaining allele of the same gene occurs somatically and
initiates tumorigenesis21. The second somatic event in individuals with a germ line
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mutation often occurs via loss of heterozygosity (LOH)28 and is generally a larger
molecular event such as a structural chromosome aberration31. Inheritance of a single
mutated allele is sufficient for tumor susceptibility, as only one additional mutation is
required for complete loss of gene function20, and inactivation of the normal remaining
copy in the susceptible tissue is usually the rate-limiting step for tumor development33.
Thus, although the cancer predisposition has a dominant pattern of inheritance, the
oncogenesis is recessive34.
An inherited cancer syndrome can be suspected by typical clinical signs; a family
history with multiple close relatives from several generations affected with the same type
of cancer, an earlier age of onset than in sporadic cases of the same cancer type, and
multiple primary tumors4. Cancer syndromes not only increase the risk of malignancy, but
some of the conditions are also associated with non-malignant features such as benign
tumors and congenital anomalies which can help in identifying the syndrome31. However,
genetic heterogeneity is common among these conditions and because of phenotypic
variability, mosaicism in which only a portion of cells contain the mutation, age-related or
reduced penetrance, and gender-specific differences, many families with a cancer
syndrome do not fulfill these criteria27,35. Cancer is also relatively common in the general
population, and it is therefore possible to have familial clustering of related cancers by
chance without an inherited component27. In families where the predisposing gene
mutation has been identified, the cancer risk of healthy relatives can be assessed by
genetic counseling and predictive genetic testing.
2. The Neurofibromatosis 2 disease
The neurofibromatoses (NFs) are a group of cancer syndromes characterized by the
development of nerve sheath tumors36. Two main forms of the NFs exist; NF1 and NF2,
for which the diagnostic criteria were formulated at the National Institutes of Health (NIH)
Consensus Development Conference in 198737. However, also schwannomatosis is
sometimes grouped to the NFs. The disorders belong to the phakomatoses, a group of
tumor syndromes characterized by benign lesions were malignant transformation occurs
only rarely38,39. The most common Neurofibromatosis 1 (NF1), also called von
Recklinghausen disease, is an autosomal dominant disorder caused by mutations in the
NF1 tumor suppressor gene on chromosome 17q11.2 coding for neurofibromin. NF1
affects approximately 1 in 3500 individuals, and leads to the formation of cutaneous and
plexiform neurofibromas, café-au-lait patches, iris Lisch nodules, skin fold freckling, optic
nerve gliomas, and bony dysplasia40. Schwannomatosis, a peripheral-nerve tumor
syndrome estimated to have an incidence of 1 in 30 000, is induced in some patients as a
result of a mutation in the INI1/SMARCB1 tumor suppressor gene on chromosome
22q11. The disorder is characterized by multiple schwannomas without the presence of
vestibular tumors41,42.
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Neurofibromatosis 2 (NF2 [MIM 10100]) is an autosomal dominantly inherited tumor
suppressor syndrome which was described already in 182243 and its heredity first
reported in 192044. The disease is rare, affecting approximately 1 in 33 000 individuals45,
although a study in Finland estimated an even lower occurrence of 1 in 87 00046. NF2 can
be diagnosed when the criteria in Table 1 are fulfilled.
Table 1. Diagnostic criteria for NF2. The criteria include the main NIH criteria with
additional Manchester criteria. Adapted from Evans 200947.
Main criteria Additional criteria
Bilateral vestibular schwannomas or
Family history of NF2 and
1) Unilateral VS or
2) Any two of: meningioma, glioma, neurofibroma,
schwannoma, posterior subcapsular lenticular
opacities
Unilateral VS and any two of: meningioma, glioma,
neurofibroma, schwannoma, and posterior
subcapsular opacities
or
Multiple meningioma and unilateral VS or any two of:
glioma, neurofibroma, schwannoma, cataract
NF2 predisposes to the development of multiple benign tumors of the nervous system,
and the hallmark of the disease is bilateral schwannomas of the eighth cranial (vestibular)
nerve (Fig.1). Schwannomas are encapsulated tumors of the Schwann cells. Normally
Schwann cells grow around the neurons and produce the myelin sheath that surrounds
axons in the peripheral nervous system. Over 90% of NF2 patients develop bilateral
vestibular schwannomas (VS), but also schwannomas of other cranial and peripheral
nerves are present in 25-50% of patients. The other main tumor features of NF2 are often
multiple intracranial meningiomas (in 50% of patients, Fig.1), and some low grade central
nervous system (CNS) malignancies such as ependymomas (in 20-50% of patients,
Fig.1) and very rarely astrocytomas. Meningiomas are slowly growing mostly benign
tumors arising from the brain and spinal cord meninges, whereas ependymomas form
from the ependymal cells of the ventricular lining. At least two-thirds of individuals with
NF2 develop spinal tumors; schwannomas, meningiomas, and ependymomas, which are
often the most challenging to manage. Also ocular manifestations are common in NF2
patients and include reduced visual acuity and cataract (in 60-80% of patients). About
70% of patients have skin tumors, most of which are schwannomas, and café-au-lait
patches are reported in 40% of patients. Many NF2 patients also form peripheral
neuropathy48,49.
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Figure 1. Tumors in NF2. An MRI-scan of an NF2 patient with the typical NF2-
associated tumors; bilateral vestibular schwannomas (VS), meningioma (M), and
ependymoma (E). Picture from Dr Stéphane Goutagny (Hôpital Beaujon, France).
NF2 generally presents in young adulthood with an average age of onset of symptoms
between 18 and 24 years, but ranging from birth to 70 years. Diagnosis of the disease is
delayed on average for 7 years with a mean age of diagnosis of 27 years. Most NF2-
affected individuals form bilateral VS by the age of 30 years and develop symptoms such
as hearing loss, tinnitus (ringing in the ears), and imbalance. The preference for tumors
on the vestibular nerve remains unexplained. NF2-associated tumors are usually slowly
growing and only rarely progress to malignancy, but their anatomical location and
multiplicity can compress nearby nerves, causing pain and nerve dysfunction, or increase
cranial pressure, leading to a variety of symptoms. The tumors gradually cause deafness,
balance disorder, paralysis, and increasing neurological problems, and most patients will
eventually need wheelchair assistance. NF2 patients face significant morbidity and
reduced life expectancy; the average age of death is 36 years with a mean survival of 15
years from diagnosis. However, the actuarial survival is 60 years and improving with
earlier diagnosis and better treatment in specialty centers. As the NF2-deficient tumors
are not malignant, conventional chemotherapy is ineffective. Treatment of symptomatic
NF2 tumors is therefore primarily surgical, although radiation therapy is also occasionally
used48,50.
2.1. The NF2 gene
The NF2 syndrome develops as a result of inactivation of the NF2 tumor suppressor
gene, which is the only gene known to be associated with the disease. The NF2 gene
was mapped to chromosome 22 in 198751,52 and identified on chromosome location
22q12.2 in 1993 (Fig.2)53,54. This gene fulfills the criteria for a classic tumor suppressor;
transmission of the mutant gene through the germline of patients predisposes to tumor
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formation, which is initiated by a somatic mutation of the remaining wild-type (WT) copy of
the gene51,55.
The NF2 gene contains 17 exons and has two major splicing isoforms, isoform 1 and
isoform 2 (Fig.2). Isoform 1 is expressed from exons 1-15 and 17, whereas isoform 2 has
a 45 base pair (bp) insertion with a termination codon that prevents translation of exon
17, and is therefore coded by exons 1-1656. The gene has an open reading frame (ORF)
of 1788 bases distributed over 110 kilobases (kb) of DNA, and produces mRNAs of three
different sizes; 7 kb, 4.4 kb, and 2.6 kb53,54. Even though the phenotype of the NF2
disease is highly restricted, the NF2 gene is widely expressed in a variety of cell types
from different tissues56,57.
Figure 2. The NF2 gene. A. The NF2 gene is located on chromosome 22 (left), at the
position 22q12.2 as shown in the ideogram (right). B. Schematic diagram of the NF2
gene exon organization and its two main isoforms. Each exon is indicated by the
numbered boxes and above each box is the size of that exon in base pair. Numbers
below each exon border indicates the position of the first codon of that exon. The
alternatively spliced last exons 16 and 17 are shown in red and blue.
Orthologous genes to the human NF2 have been identified in many species. Among
the metazoans, the gene is phylogenetically conserved in invertebrates, fish, mammals,
and birds58. The murine Nf2 gene maps to chromosome 11 in a region homologous to
human chromosome 22, and shows 90% nucleotide sequence identity with the coding
region of the human NF2 gene59-61. No NF2 homolog has been found in the genomes of
fungi, plants, or protozoa, implying that NF2 function is specific to multicellular
metazoans58.
In addition to its tumor suppressor function, the NF2 gene is essential for normal
development and viability at least in fruit fly, roundworm, zebrafish, and mice62-65. Nf2
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knockout (Nf2-/-) mice die early during embryogenesis at day 7 of a failure to form extra-
embryonic ectoderm and initiate gastrulation64. Heterozygous Nf2 mice (Nf2+/-) are viable
and develop a wide range of malignant highly metastatic tumors, predominantly
osteosarcomas, fibrosarcomas, and hepatocellular carcinomas66, but not the tumors
typically observed in NF2 patients. However, targeted inactivation of Nf2 specifically in
Schwann cells or meningeal cells in conditional Nf2 mutant mice, leads to the formation
of schwannomas and meningiomas that resemble NF2 tumors67,68.
2.2. NF2 gene mutations
Consistent with the Knudson’s two-hit theory of tumorigenesis, tumor development
initiates when both alleles of the NF2 gene are inactivated. The NF2 gene has a high
estimated mutation rate of 6.5x10-6, and the occurrence of NF2 without family history is
therefore common69. Mutations of the NF2 gene are frequently detected not only in
tumors of the NF2 disease, but also in their sporadic counterparts and in some malignant
tumors unrelated to the syndrome.
2.2.1. Mutations in the NF2 disease
In the NF2 syndrome, a germline defect in one of the NF2 alleles is inherited and followed
by somatic inactivation of the remaining allele in individual Schwann or meningiomal cells
at some point later in life, which induces tumorigenesis. The disorder has a high
penetrance of nearly 100% and individuals who inherit a pathogenic mutation will develop
the disease in an average lifetime48. As a result of the high spontaneous mutation rate of
the NF2 gene, about half of NF2 cases represent de novo germline mutations without a
family history69. Mutations in the NF2 gene are detected in 88% of familial and 59% of
sporadic NF2 patients70, indicating that loss of the NF2 protein is the main rate-limiting
step in NF2 tumor formation71. However, mathematical modeling of VS formation in NF2
patients has suggested that at least one more mutational event, in addition to the biallelic
NF2 inactivation is required for human schwannoma development72.
More than 200 different mutations in the NF2 gene have been described. The majority
of the alterations are point mutations, of which C>T transitions causing nonsense
mutations are the most common (Fig.3). Although truncating mutations are the most
frequent germline events with nonsense and frameshift mutations occurring in
approximately 50% of families and splice site mutations in 25%, also single and multiple
exon deletions are detected. In contrast, missense mutations occur with an extremely low
frequency in only 5% of NF2 families. Inactivating mutations in the NF2 gene are fairly
evenly distributed throughout the first 15 exons, except for exon 9 which has a low
frequency of mutations. However, exons 1-15 contain six CGA codons which are
mutation hotspots for C>T transitions in CpG dinucleotides. Interestingly, no mutations
have been detected in the alternatively spliced exons 16 and 1773,74.
Partial correlation between the type of mutation and the NF2 disease phenotype has
been observed. In general, patients with truncating nonsense or frameshift NF2 mutations
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have a more severe disease, whereas missense mutations, large deletions, or somatic
mosaicism are associated with mild phenotypes74-80. Patients with constitutional
truncating mutations typically have an earlier onset and increased prevalence of
meningiomas, spinal tumors, and peripheral nerve tumors leading to a greater disease-
related mortality than those with other NF2 mutations75,81-83. The phenotype is more
variable in patients with splice-site mutations, with a milder disease if occurring in the 3'
half of the gene84. The NF2 syndrome has a high rate of mosaicism with 25-33% of
patients without a family history of the syndrome, and especially milder cases, having a
mosaic disease85-87. Mosaicism is particularly likely when tumors are predominantly on
one side of the body, and 60% of NF2 patients with unilateral vestibular schwannoma
(UVS) are somatic mosaics87.
Figure 3. Comparison of constitutional and somatic NF2 gene mutations by
predicted effect. FS = frameshift, NS = nonsense, MS = missense, SS = splice site.
Other mutations include both large deletions and insertions and in-frame deletions and
insertions. Combined from Ahronowitz et al. 200774 and Baser et al. 200673.
2.2.2. Mutations in NF2-related sporadic tumors
In accordance with the two-hit model, acquired mutations in the NF2 gene contribute also
to the development of sporadic tumors53-55. Schwannomas and meningiomas are among
the most common brain tumors in humans, accounting for about 30% of adult CNS
neoplasms. However, only 3-7% of all schwannoma and 1% of meningioma patients have
NF246,48. Sporadic VS has an annual incidence of approximately 1.9 per 100 000
individuals88, and UVS constitute 5-10% of all intracranial tumors89. Meningiomas account
for 25% of primary intracranial neoplasms90, with an annual incidence of about 7.1 per
100 000 individuals91, whereas the annual incidence of ependymoma is 2-4 per million in
Europe92. The sporadic tumors present with similar symptoms as their syndromic
counterparts but later in life, with a median age of diagnosis of 48 years for
schwannomas and 58 years for meningiomas46.
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Somatic biallelic inactivation of the NF2 gene is detected in most sporadic
schwannomas93, in 50-70% of sporadic meningiomas94, and in 5-10% of sporadic
ependymomas95, suggesting that NF2 inactivation is the main predisposing event in the
formation of most schwannomas and about half of meningiomas74. Partial or total deletion
of chromosome 22 leading to LOH of the NF2 gene is the most consistent alteration
reported in sporadic meningiomas96-98, and it is associated with NF2 mutations in the
tumors94,99 although the frequency of NF2 mutations varies among meningioma
subtypes100. LOH of the NF2 region is also detected in sporadic ependymomas101. In
addition, the two NF2 alleles are commonly altered in tumors from schwannomatosis
patients, but the mutations differ between tumors in the same individual and are not found
in their non-tumor tissues, implying that they represent secondary mutations102,103.
Although the majority of somatic NF2 gene mutations are similar to germline
mutations, there are some differences between their distribution and type (Fig.3). Of the
somatic mutations in sporadic UVS over half are frameshift mutations, in contrast to
constitutional mutations that are primarily nonsense and splice site. Somatic mutations
also have the tendency to lie within the 5’ end of the transcript in sporadic meningiomas
and possibly also ependymomas, with a complete absence of mutations in exons 14 and
15 in meningiomas73,74.
In addition to mutations, also epigenetic silencing of the NF2 gene has been
described in tumors. Between 20-40% of sporadic schwannomas are inactivated by NF2
promoter methylation104,105, and aberrant hypermethylation is involved also in the
development of sporadic meningiomas106 and some ependymomas107.
2.2.3. Mutations in other sporadic tumors
Mutations in the NF2 gene are found in some sporadic malignant tumors unrelated to the
NF2 syndrome, such as in carcinomas of breast56 and colon108,109, and in melanomas56.
Somatic inactivation of NF2 has been identified in about 40% of malignant
mesotheliomas110-113, and all tumors with NF2 mutations also exhibited LOH of the NF2
region112. Coexistence of mutations and LOH at the NF2 locus has also been reported in
perineural cell tumors114, and the NF2 gene is homozygously lost in some hepatocellular
carcinoma cell lines115. In addition, allelic loss of NF2 has been described in thyroid
carcinomas116 and in gastrointestinal stromal tumors117,118. It is possible that NF2
mutations represent later stages in the tumor progression of these NF2-unrelated
neoplasms56.
Inactivation of the NF2 gene in tumors of different origin together with the studies in
heterozygous Nf2 mice that develop sarcomas and liver tumors, suggest that the NF2
gene product might have a more general role in tumorigenesis66. However, the highly
metastatic tumors of Nf2+/- mice are not observed in NF2 patients, human
osteosarcomas do not have NF2 mutations119, and the most prevalent human cancers
have not been described to contain NF2 mutations65. It is possible, however, that abolition
of NF2 function occurs also through alternative mechanisms to mutation, such as through
epigenetic silencing of the NF2 gene or post-translational inactivation of the NF2-encoded
protein103.
Review of the literature
21
3. The Cytoskeleton
3.1. Composition of the cytoskeleton
The cell cytoskeleton functions as dynamic scaffold providing structure and intracellular
organization. This network of filamentous polymers and regulatory proteins is essential for
many processes as it controls cell shape, adhesion, migration, and various signaling
pathways. The cytoskeleton consists of three kinds of protein filaments; microfilaments,
intermediate filaments, and microtubules (Fig.4).
Figure 4. Cytoskeletal filaments. The cytoskeleton is composed of three main types of
filaments; actin filaments (AF), intermediate filaments (IF), and microtubulus (MT).
Microfilaments, or actin filaments, are the thinnest cytoskeletal filaments with a
diameter of 5-9 nm. In these filaments, globular actin (G-actin) monomers are assembled
into filamentous polymers (F-actin). Actin filaments are present throughout the cell, but
most highly concentrated in the cortex on the inner face of the plasma membrane, where
they link transmembrane and cytoplasmic proteins together. The flexible polarized actin
filaments provide mechanical strength and generate force, this way regulating both the
shape and movement of cells120.
Intermediate filaments are fibers of an average of 10 nm in diameter, constructed of a
heterogeneous class of intermediate filament proteins, such as keratin, vimentin, and
lamin. These highly stable filaments create a fibrous network that increases the
mechanical strength of the cytoskeleton. Intermediate filaments organize the internal
structure by anchoring organelles but also serve as major components of the nuclear
envelope. In addition, the filaments participate in cell connections, and are therefore
involved in regulating adhesion121.
Microtubules are long, hollow tubes of about 25 nm in diameter built up by dimers of
α- and β-tubulin. These long and dynamic filaments typically extend from the centrosome
to the cell periphery. Microtubules determine the positions of membrane-enclosed
organelles, and these polymers are essential for directing cell transport and for cell
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division122. The cytoskeletal polymers formed by actin filaments, microtubules, and
intermediate filaments interact with each other through many regulatory proteins that link
the filaments to networks, which control the mechanics of the cell123.
3.2. Regulation of cell shape and motility
Cell migration and morphological changes involve alterations in the cytoskeleton, the cell
membrane, and cell-substrate adhesions. Especially actin and actin-associated proteins
are involved in cell-shape determination, and a large number of actin-binding proteins
regulate the assembly and organization of the actin cytoskeleton124. By polymerizing actin
filaments and microtubules against membranes, the cytoskeleton generates the forces
that enable the cell to move and to change shape123.
Actin filaments form many types of cell-surface structures. Branched networks of actin
filaments make up sheet-like structures termed the lamellipodium which are often present
at the front of motile cells (Fig.5). The thin 0.1-0.2 μm protrusive lamellipodia vary in
breadth from 1-5 μm and are filled with a crosslinked meshwork of F-actin125. Rodlike
extensions called filopodia often protrude from the lamellipodia (Fig.5). These are
protrusions of 0.1-0.5 μm in diameter composed of parallel F-actin bundles that extend 5-
50 μm out of the cell126. These dynamic structures are pioneers during protrusion
formation, functioning as sensors for cells to probe their environments. They have an
important role in cell migration guidance, wound healing, adhesion to the ECM, and
neurite outgrowth. Short filopodia mostly embedded in the cell edge are called
microspikes. Although filopodia are commonly found in association with lamellipodia, they
can also form independently127,128. In addition to lamellipodia and filopodia, non-muscle
cells contain actin-rich stress fibers (Fig.5). Stress fibers are bundles composed of
antiparallel arrays of actin filaments associated with myosin II. These acto-myosin
structures provide the contractile force required for cell motility, adhesion, and
morphogenesis129.
The small GTPases of the Rho family are linked to the modulation of cell morphology
as they are critical regulators of the actin cytoskeleton. The proteins are a part of a
complex network of essential signal transduction pathways transmitting signals from
extracellular stimuli to the downstream target effectors. Rho GTPases act as molecular
switches by cycling between inactive GDP-bound and active GTP-bound states, and their
activation is mediated by guanine nucleotide exchange factors (GEFs), while inactivation
is promoted by GTPase activating proteins (GAPs). Twenty different mammalian Rho
GTPases have been identified, but the best characterized members are RhoA (Ras
homologous member A), Rac1 (Ras-related C3 botulinum toxin substrate 1), and Cdc42
(cell division cycle 42). Although there is cross-talk between the family members and the
Rho GTPases can be activated in series, each protein induces specific morphological
changes. Cdc42 triggers the formation of filopodia, Rac1 promotes lamellipodium
development, whereas the formation of stress fibers and focal adhesions is regulated by
RhoA130.
Cell motility is a complex process, requiring constant restructuring of the actin
cytoskeleton131. The motility of a cell can be divided into three essential steps (Fig.5).
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First, as a result of actin filament polymerization, protrusive structures such as
lamellipodia and filopodia extend from the front of the cell in the direction of migration.
Second, the cell attaches to the surface by forming new adhesions with the substratum
under the leading edge. The formed protrusion is stabilized by attaching to the
surrounding through receptors such as integrins whereas adhesion at the rear
disassembles. Third, the rest of the cell body is translocated through actomyosin-based
contractile forces. Stress fibers pull the rear of the migrating cell forward, leading to
retraction of the trailing edge132.
Figure 5. Cell migration. The cell migration process can be schematized into three
separate phases. 1. Protrusion of the leading edge in the form of lamellipodia and
filopodia. 2. Attachment of the leading edge through the formation of new focal adhesions
and deadhesion of the rear. 3. Traction of the bulk of the cell through stress fiber
contraction.
Localized activation of the Rho GTPases is essential for migration. The initial
response of a cell to a migration-promoting agent is to polarize and extend protrusions in
the orientation of migration to establish directionality. Cdc42 which is active in the front of
migrating cells is a regulator of both cell polarity and filopodia formation, and activation of
Rac at the leading edge promotes lamellipodia formation. Rho in contrast, acts in the rear
of the cell and Rho-regulated contractility is required for tail retraction133.
3.3. Actin cytoskeleton in cancer
As the actin cytoskeleton is critical for most cellular activities, malfunction of cytoskeletal
proteins results in various human diseases, including cancer. The cytoskeleton plays an
essential role in many of the functions that are important for cancer cells and their
invasion, such as the cell cycle, morphogenesis, and migration. Cytoskeletal alterations
are linked to changes in cell proliferation and ultimately tumor formation, since
disorganization of the cytoskeleton is often associated with cellular transformation134.
Malignant cells display altered morphology with changes in their actin cytoskeleton, and
often the expression of many actin-associated proteins in these cells is altered135. Several
of the Rho GTPases that regulate both morphogenesis and migration are overexpressed
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in various tumors, and contribute to most steps of cancer initiation and progression134,136.
Unregulated activity of Rho GTPases has been linked to cell transformation, invasion,
and motility, and deregulation of these proteins correlates with poor clinical
outcome136,137. Also NF2-deficient schwannoma and meningioma cells display
cytoskeletal abnormalities138-141.
4. ERM proteins
The ERM protein family consists of three closely related molecules; ezrin142,143,
radixin144,145, and moesin146. These proteins belong to a larger superfamily of band 4.1-
members, which regulate interactions between the cytoskeleton and plasma
membrane147. The founding member of this family, protein 4.1, is an important structural
molecule particularly in erythrocytes, where it regulates the physical properties of
membranes by stabilizing spectrin-actin interactions, this way controlling red blood cell
shape148. Band 4.1-protein family members are defined by the presence of a homologous
amino (N)-terminal module of approximately 300 amino acids, a region called the FERM
(Four.1 protein, Ezrin, Radixin, Moesin)-domain149. This highly conserved globular
structure is composed of three subdomains; F1, F2, and F3, that are arranged like a
cloverleaf. The F1 subdomain is structurally similar to ubiquitin, F2 to the acyl-CoA-
binding protein, and F3 to a module in phosphotyrosine binding (PTB)/pleckstrin
homology (PH), and Enabled/VASP homology 1 (EVH1)150. The FERM-domain is
involved in targeting the proteins to the plasma membrane and in mediating membrane-
cytoskeleton interactions147,149. The superfamily of FERM-domain proteins comprise more
than 50 mammalian members, most of which are involved in signaling at the cell
cortex151.
Genes coding for ERM proteins have been identified in all multicellular metazoan
organisms analyzed, but the number of family members varies from one to three
depending on species, and all non-mammalian genomes sequenced so far contain only
one ERM gene152. The three ERMs in humans are encoded by genes residing on
different chromosomes; the ezrin gene EZR is located on chromosome 6q25.3143, the
radixin gene RDX on chromosome 11q23153, and the moesin gene MSN on chromosome
Xq11.2154. The ERM proteins have an overall homology of 75-80% on the amino acid
level, and they share a similar structure consisting of three domains: the N-terminal
FERM-domain (residues ~1-300 in ezrin), a highly charged α-helical segment (residues
~300-470 in ezrin), and a small charged carboxy (C)-terminal domain (residues ~470-585
in ezrin)155 (Fig.6). The α-helical domain of the proteins consists of three extended
helices156, whereas the ~100 residue C-terminus is composed of a β-sheet and four major
and two minor α-helices that adopt an elongated structure150. The exceptionally high level
of identity among the ERMs implies that they arose by gene duplication within
vertebrates. The high degree of structural conservation between the proteins also
indicates that they have similar functions, and that their activities might be partially
interchangeable157. The single ERM proteins of non-vertebrates, such as Drosophila
moesin (D-moesin), which is 56-58% homologous to human moesin and ezrin, may
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therefore perform all the functions that the three ERM proteins possess in vertebrate
tissues158, where the ERMs have some functionally unique properties159.
Figure 6. Members of the ERM protein family. The overall homology of the full-length
proteins compared with human ezrin is indicated in the last column, and the length of the
molecules is in amino acids. The identity of different domains compared to the
corresponding domains of human ezrin is shown beneath the relevant domains. Modified
from Turunen et al., 1998160.
Most cell types express one or several of the ERM family members161-163, but their
expression is developmentally regulated and organ and cell type specific. Ezrin is
predominantly expressed in the intestine, lung, kidney, and stomach, moesin in lung and
spleen, and radixin in liver144,161. In these organs, ezrin is expressed in epithelial and
mesenchymal cells, moesin in endothelial and hematopoietic cells, and radixin in
hepatocytes161,164.
The ERM proteins interact with common molecules, localize similarly within cells, and
have identical models of regulation. Studies in ERM knockout mice mostly support
redundant functions for the three proteins157, as defects are observed exclusively in the
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organs where only one of the ERMs is expressed. A lack of ezrin, the only ERM protein
expressed in the intestinal epithelium, results in abnormal villus morphogenesis and the
ezrin-deficient mice die by 3 weeks of age as a consequence of defects in the
gastrointestinal tract165. Ezrin also plays a role in the formation of apical secretory
canaliculi in gastric parietal cells, and therefore adult ezrin knockdown mice suffer from
loss of gastric acid secretion from these cells in their stomachs166. Mice lacking radixin
develop normally but show mild liver defects167 and deafness168, whereas moesin-
deficient mice show no obvious abnormalities169. The limited phenotypes of the ERM
knockout mice could reflect compensation by other family members170.
All three ERM proteins localize in the cell cortex to actin containing regions of
membrane remodeling such as filopodia, microvilli, membrane ruffles, and cell adhesion
sites161-163,171,172. Ezrin is, for example, detected in intestinal microvilli173, radixin at the cell
adherens junctions (AJs)144 and in the cleavage furrow of dividing cells174, and all ERM
proteins are present in neuronal growth cones175,176. In addition to their membrane
localization, the proteins are found in soluble forms in the cytoplasm163,177, and in the
nucleus, where at least endogenous ezrin and moesin are relocated in a cell density-
dependent manner178.
Figure 7. The ERM family members function as linkers between the cell membrane
and actin cytoskeleton. The N-terminus (N) of the ERMs binds to transmembrane
receptors whereas the C-terminal domain (C) is connected to actin filaments.
The ERMs provide a structural link between the cytoskeleton and membrane by
connecting transmembrane proteins to cortical actin filaments, this way strengthening the
cell cortex151. This regulated attachment is essential for modulation of cell morphology,
control of cell adhesion and motility, and integration of signal transduction pathways from
membrane proteins157. The FERM-domain localizes the ERMs to the plasma membrane,
where they interact with membrane proteins via their N-terminal domains and with
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cytoskeletal components by their C-terminal ends (Fig.7)179. The ERM proteins have the
ability to heterodimerize with each other180,181 and they share many binding partners. All
three ERMs associate directly with the cytoplasmic tails of transmembrane proteins such
as the hyaluronic acid receptor CD44182,183, leukosialin CD43184, intracellular adhesion
molecules ICAM1, ICAM2, and ICAM3184-186, and the Na+/H+ exchanger (NHE1)187. The
ERMs can also associate indirectly to ion channels and receptors via scaffolding proteins
NHE-RF (NHE regulatory factor)/EBP50 (ezrin-binding phosphoprotein 50)188,189 and
exchanger 3 kinase A regulatory protein (E3KARP)190. The ERM proteins bind actin
filaments through a conserved actin binding site (ABS) comprising the 34 most C-terminal
residues containing the actin binding motif KYKTL191-193, but besides the C-terminus,
additional ABSs are present in the FERM-domains of the proteins194,195. Suppression of
ERM function leads to alterations in the cortical actin cytoskeleton196, destroys cell
surface structures, and disrupts cellular adhesion172, indicating that the proteins have an
important role in organizing the actin cytoskeleton. The ERM proteins also associate with
many cytoplasmic signaling molecules and regulate signal transduction for example
through the Rho GTPase pathway by interacting with both positive GEFs and negative
Rho guanine-dissociation inhibitor (RhoGDI) regulators197,198.
4.1. Ezrin
Ezrin (cytovillin, p81) was the first characterized ERM member and represents the
prototype of the family. The ezrin gene EZR (VIL2) located on chromosome 6q25.3
consists of 13 exons distributed over approximately 24 kb of genomic DNA143,199. The
gene codes for a 585 amino acid protein with a molecular mass of 81 kilodalton
(kDa)142,143. The identity between the mammalian ezrin family members is 97%, making
the family one of the most conserved classes of mammalian proteins160. Ezrin was
originally identified as a cytoskeletal component of intestinal microvilli173,200, and a
substrate for tyrosine kinase201. Although ezrin is highly expressed in some tissues, such
as the intestine, intermediate levels of the protein are found in most tissues except for
liver and muscle142. Ezrin is especially enriched on the apical surface of polarized
epithelial cells161.
As a plasma membrane-cytoskeleton crosslinker, ezrin serves as a binding partner for
many different proteins, including adhesion molecules, ion transporters, scaffolding
proteins and signaling molecules157. Ezrin, like the other ERMs, contains the high affinity
ABS in its C-terminus191, but also N-terminal residues 13-30 and 281-310 are essential
for both the G- and F-actin-binding activity of ezrin194,195. By affecting actin organization,
the protein regulates cell morphology and the formation of various surface structures.
Expression of full-length ezrin in cultured cells does not induce morphological changes,
but truncated proteins mimicking active molecules, provoke the appearance of microvilli
and protrusions. Removal of the last 21 C-terminal amino acids is sufficient to generate
this cell-extension phenotype195, whereas overexpression of the N-terminal half of ezrin is
able to suppress the formation of microvilli202. The N-terminal domain apparently
regulates the morphogenic activity of the C-terminal domain in full-length ezrin195,203.
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Ezrin has oncogenic activities with a positive role in tumorigenesis. Although it does
not represent a conventional oncogene as no EZR gene mutations have been
detected204, the protein enhances malignant transformation, survival, motility, and tumor
invasion170. Elevated ezrin levels are associated with increased cell proliferation205, and
both transformed rat fibroblasts206,207 and mouse sarcoma cells208 express enhanced
amounts of ezrin. The protein is required for invasion of many different cancer cells209-211
and is an essential regulatory molecule for tumor metastasis212. Ezrin is upregulated in
many metastatic tumors213-216, and promotes metastasis of at least osteosarcomas217,
rhabdomyosarcomas218, mammary carcinoma219, and melanoma cells220. Ezrin is
dynamically regulated during the metastatic cascade of osteosarcoma; it is active during
the onset and early stages of metastatic progression and in later phases as established
large metastases expand, but downregulated in between219. As a component of cell
surface structures, the protein has an important function in mediating both cell-matrix and
cell-cell interactions, and may therefore have a role in the control of adhesion between
cancer cells and the surrounding tissue, this way affecting metastasis and invasion212,221.
Ezrin expression, which is often altered in tumors, associates with tumor progression and
is a prognostic indicator in several malignancies. Upregulation of ezrin correlates with
poor clinical outcome at least in carcinomas of the breast222, endometrium223, head and
neck224, ovary210, and colorectum225,226, and in melanomas227,228 and different
sarcomas217,229.
5. The NF2 protein Merlin
5.1. Properties of merlin
The NF2 gene encodes the tumor suppressor protein merlin (or schwannomin). Merlin
shares overall structural similarity with the ERM family of proteins after which it was
named (moesin-ezrin-radixin like protein)53,54. Similarly to the ERM proteins, merlin
contains three structural domains (Fig.8); the N-terminal FERM-domain (residues ~1-314)
consisting of three subdomains F1-F3, an α-helical region (residues ~315-491), and a
charged C-terminal domain (amino acids ~492-595). The FERM-domain of human merlin
is highly conserved and over 60% identical with the ERM-members, whereas the
homology of the α-helical and C-terminal domains is only 20-30%. This makes the overall
identity of merlin with the ERM proteins 45% (Fig.6)160. Due to the marked sequence and
structural similarity, merlin and ERMs are believed to have arisen early in metazoan
evolution from a common ancestor58. However, merlin contains 18 unique N-terminal
residues outside the FERM-domain, which form an extended tail and are not conserved
in the ERMs58,230-232.
Merlin exists as two major isoforms as a result of alternative splicing of exon 16.
Isoform 1, produced from exons 1-15 and 17, is a 595 residue protein with a molecular
mass of 66 kDa54. In isoform 2, exon 16 inserts 11 amino acids and a stop codon
resulting in a 590 residue protein (Fig.2). Thus, the isoforms are identical over the first
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579 residues but differ in their C-terminal sequences as isoform 1 has a hydrophobic
helical C-terminus whereas isoform 2 contains a non-helical hydrophilic sequence56.
Isoform 1 is the predominant type expressed in the eight cranial nerve56, although isoform
2 is slightly more prelevant in general233. Also a number of low transcript isoforms of
merlin are found233-235, but their functional significance is unclear.
Figure 8. Domain structure of merlin isoform 1. Merlin consists of three distinct
regions; the FERM-domain (exons 1-9), the α-helical domain (exons 10-13), and the C-
terminus (exons 14-17). The FERM-domain is made up from three subdomains; F1
(residues 19-100), F2 (residues 101-215), and F3 (residues 216-313). Merlin also
contains an N-terminal tail region (residues 1-18).
Merlin is evolutionally conserved across species indicating that it has an important
function58. The mouse protein is 98% identical to human merlin and similarly alternatively
spliced59-61. A merlin ortholog exists also in Drosophila, called D-merlin that shares 55%
amino acid identity with the human protein, but does not have alternatively spliced
isoforms158.
Merlin is expressed in many tissues during rat embryogenesis, but has a more
restricted tissue distribution in the adult organism236. The protein is widely expressed at
low levels also in a variety of human tissues, but at the cellular level the presence of
merlin has been demonstrated mainly in smooth muscle cells, neurons, and Schwann
cells237-239. Although the protein is expressed in Schwann cells, meningothelial cells, and
ependymal cells, the expression is not as pronounced as in neurons and other glia238,240,
even though the NF2-associated tumors predominantly arise from these cell types.
Despite the presence of both ERM proteins and merlin in Schwann cells, the absence of
merlin function alone results in the development of schwannomas93.
5.2. Functions of merlin
Merlin is the first example of a human tumor suppressor, a gatekeeper, that serves as a
cytoskeletal component between the membrane and cytoskeleton. Consistent with its
function as a negative growth regulator, merlin plays an important role in inhibiting cell
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proliferation at high cell densities. Overexpression of merlin suppresses the proliferation
of mouse fibroblasts241, rat242 and human243,244 schwannoma cells, and human
meningioma cells245. Reintroduction of merlin in NF2-deficient schwannoma and
mesothelioma cells, inhibits proliferation by inducing cell cycle arrest at G0/G1, but also
increases apoptosis243,246. Furthermore, merlin is able to reverse the malignant phenotype
of Ras transformed NIH 3T3 cells and restore their contact inhibition of cell growth247,248.
Conversely, loss of D-merlin results in cellular overproliferation249, and reduction of merlin
expression enhances cell proliferation in Schwann-like250 and glial251 cells. Inactivation of
merlin leads to exit from contact-dependent growth inhibition252,253 and promotes
progression through the G1 cell cycle phase254. Thus, merlin has distinct cell density
dependent activities. It is inactive as a tumor suppressor in subconfluent cells, but
becomes activated as the cells approach confluence, thereby affecting contact inhibition
of growth253,255. Although merlin and the ERMs share some common functions, there is no
redundancy for merlin’s growth inhibitory mechanism.
Many tumor suppressors undergo nucleo-cytoplasmic shuttling that affects their
function19. Similarly, endogenous merlin is targeted to the nucleus in a cell cycle specific
manner. The protein is accumulated perinuclearly at the G2/M phase, and localized to the
nucleus at early G1 in cultured cells256, whereas in schwannoma cells of VS, merlin
resides in the cytoplasm during G0/G1 and translocates to the nucleus at S phase257. No
nuclear localization signal has been identified in merlin, but a nuclear export sequence
(NES) is present in exon 15 between residues 535-551, while exon 2 contains a
cytoplasmic retention factor258. Studies have suggested that the FERM-domain is
sufficient for nuclear entry259-261, whereas the C-terminus can inhibit nuclear accumulation
in the full-length molecule unless it associates with the N-terminus261. The nucleo-
cytoplasmic shuttling of merlin is tightly regulated and dependent not only on the cell
cycle phase, but also on cell density and adhesion256. Even though the nuclear function of
merlin is not completely elucidated, it has been shown that merlin interacts with and
inhibits the function of the CRL4DCAF ubiquitin ligase upon entering the nucleus261.
Merlin, like the ERM proteins, acts as a linker between plasma membrane molecules
and cytoskeletal components. Many merlin-interacting proteins have been identified, and
these include both membrane-associated and intracellular molecules262. In analogy with
ERM proteins, merlin associates via its FERM-domain with membrane proteins including
CD44263, β1-integrin264, paranodin265, and NHE-RF188. Merlin also binds several
molecules through its C-terminus, such as βII-spectrin266, hepatocyte growth factor-
regulated tyrosine kinase substrate (HRS)267,268, and syntenin269. In addition, merlin
directly interacts with cytoskeletal microtubules270,271 and F-actin271. The high affinity ABS
present in the C-terminus of the ERM proteins is not conserved in merlin191,193, but
instead merlin interacts with F-actin through two ABSs located in its N-terminus between
residues 1-27 and 280-323231,271,272. However, the actin binding of merlin is weaker than
that of ERM proteins272, but merlin is able to associate indirectly with the actin
cytoskeleton through the ERMs273-276, spectrin266, or paxillin277.
In addition to the growth inhibitory properties, merlin also has morphogenic effects. It
localizes underneath the plasma membrane in cultured cells239,259,263,278. The membrane
targeting of merlin requires proper folding of the FERM-domain231,279, and therefore
mutants with intact C-terminal domains but with altered N-termini mislocalize around the
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nucleus and diffusely in the cytoplasm279,280. However, also full-length D-merlin has a
punctate distribution in the cytoplasm and at the plasma membrane, and is concentrated
in endocytotic compartments158. The interaction between merlin and F-actin and their
colocalization in areas of membrane remodeling263,278,281,282 suggests that merlin plays a
role in maintaining cytoskeletal organization. Overexpression of merlin induces the
formation of cell extensions, surface blebs, membrane ruffles, and filopodia259,263.
Interestingly, also merlin-deficient human schwannoma and meningioma cells display
cytoskeletal defects and develop multiple cell extensions, show membrane ruffling and
disorganized stress fibers, and exhibit increased cell spreading138-141. Reintroduction of
merlin in these NF2-deficient cells reverses the aberrant cytoskeletal phenotypes141,283,284.
Merlin also regulates other actin cytoskeleton-mediated processes, and has an
inhibitory effect on cell motility, spreading, and adhesion285,286. Although the molecular
mechanism by which merlin regulates motility is not known, several possibilities exist.
Focal adhesions are dynamic protein complexes that link the ECM, integrins, and the
actin cytoskeleton together to form cell-substrate adhesions. Merlin localizes to focal
adhesions in fibroblasts287, and interacts with the focal-adhesion component paxillin in a
complex that contains both β-integrin and erbB2277. The role of merlin in cell migration
could be associated with the modulation of integrin signaling at focal contacts that
coordinates cell motility288. It has also been suggested that expression of merlin inhibits
invasiveness by downregulating focal adhesion kinase (FAK), an essential protein in
inducing cell motility and invasion285. Overexpression of merlin does not only impair cell
motility, but results in abnormal F-actin organization during cell spreading, and a transient
decrease of cell adhesion286. However, also reduction of merlin expression with antisense
oligonucleotides or overexpression of merlin mutants reduces cell attachment250,259,280,
indicating that merlin’s function in mediating adhesion is complex and tightly regulated.
Altered cell-matrix adhesions are typical for malignant cells and required for tumor
invasiveness and metastasis. Heterozygous Nf2 mice develop highly invasive and
metastatic tumors66, further implying that merlin plays a role in regulating cell adhesion.
However, no connection between merlin loss and metastasis in humans has been found,
and NF2 patients do not have an increase in metastatic cancer forms289.
The functional significance of the two merlin isoforms is not understood, but some
divergences between the forms have been denoted. Merlin isoform 1 binds less efficiently
than isoform 2 to several interaction partners, including NHE-RF275, βII-spectrin290,
RhoGDI291, HRS267,268, and F-actin272. In contrast to isoform 1, isoform 2 is unable to
reverse the cytoskeletal defects of merlin-deficient schwannoma cells283 and does not
impair motility or adhesion286. Whereas merlin isoform 1 inhibits schwannoma growth,
isoform 2 does not influence proliferation in rat schwannoma cells and is therefore
thought to lack growth suppressive activity242. However, merlin not only functions as a
negative growth regulator in tumor formation, but also has an important role in
embryogenesis and tissue differentiation. Interestingly, Nf2 knockout mice that express
only isoform 2 develop normally157.
Cadherin-containing AJs mediate cell-cell interactions and are important for
transducing growth arrest signals during cell contact. Merlin localizes to cell-cell
junctions240,253,291 and regulates both AJ and focal contact formation in several cell
types141,253,292,293. It colocalizes and associates with components of AJs, and controls the
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assembly and stabilization of these structures, possibly by linking these complexes to the
actin cytoskeleton. Nf2 deficiency leads to disruption of AJs and loss of contact-
dependent inhibition of growth253. Loss of AJs contributes to tumor development by
enhancing invasiveness and metastasis294, so the absence of stable AJs in Nf2-deficient
cells could therefore explain the metastatic potential of the tumors in heterozygous Nf2
mice170.
Merlin stabilizes the membrane-cytoskeleton interface and organizes the distribution
and signaling of membrane receptors151. The protein has been suggested to control cell
proliferation by regulating growth factor receptor abundance and thus signaling at the cell
surface244,252,293,295. Merlin regulates the presence of growth factor receptors by limiting
their delivery to the plasma membrane252 or by sequestering them in membrane
compartments from which they can neither signal nor be internalized293, this way blocking
downstream signaling upon cell-cell contact. Merlin is also believed to integrate receptor
tyrosine kinase (RTK) and adhesion receptor CD44 signaling at the membrane296.
According to one model, merlin and CD44 function together as a molecular switch that
regulates the growth-promoting and growth-inhibitory cell states. Upon cell contact, active
merlin binds to CD44 and negatively regulates RTK signaling255. Loss of merlin would
lead to elevated growth factor receptor levels and persistent RTK signaling regardless of
cell-cell contact, this way promoting proliferation151,296.
Furthermore, merlin is involved in several intracellular signal transduction pathways
through which it mediates the function as a negative growth regulator. It downregulates
Ras-ERK297-299, PI3K-Akt244,300, mTORC1 (mammalian target of rapamycin complex
1)254,301, Rac247,302,303, and FAK-Src285,304 signaling. Merlin has been shown to regulate cell
proliferation and survival also through the Drosophila Hippo tumor suppressor pathway. It
cooperates with the distantly related FERM superfamily member Expanded to activate
Hippo signaling305-307 that plays important roles in restricting organ size and suppressing
tumor development308. Studies suggest that merlin participates also in Mst/Lats/Yap
signaling which is the equivalent mammalian Hippo pathway308,309.
6. Regulation of Merlin and ERM activity
Post-translational modifications regulate the biological function of merlin and the ERM
proteins by several different mechanisms. The proteins can exist in active and inactive
conformations, which modulate their ability to interact with other molecules. This
conformational regulation is achieved by a combination of phospholipid-binding and
phosphorylation. Ultimately, the activity of merlin is determined by its turnover rate.
6.1. Conformational regulation
A characteristic feature within the ERM protein family is intra- and intermolecular
association by head-to-tail joining (Fig.9). The proteins can exist in dormant, monomeric
forms in which the N-ERM association domain (N-ERMAD), residues 1-296 in ezrin,
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interacts with the C-ERM association domain (C-ERMAD), residues 479-585 in ezrin310.
This intramolecular folding regulates the functional activity of ERM proteins, as
association between the ERMADs causes the proteins to adopt closed inactive
conformations, where binding sites for other interacting molecules are masked310,311.
Dissociation of the ERMADs leads to a conformational change which unmasks actin and
membrane protein recognition sites, allowing ERMs to associate with these
molecules312,313. In addition to homodimerization, the ERMs also form heterotypic
associations between family members, resulting in dimers and oligomers177,180,181,314.
According to the crystal structure of the moesin N-ERMAD-C-ERMAD complex, the C-
terminus adopts an extended structure that masks a large surface of the F2 and F3 lobes
on the FERM-domain surface in the closed conformation150. The C-terminal helices bind
the N-terminus largely independently150, implying that individual secondary structural
elements make a binding contribution leading to the high affinity of the ERMADs to each
other315. Also the α-helical domain forms independent interactions with the N-terminal
domain and together with the C-terminus they cover 25% of the accessible FERM-domain
surface156.
Figure 9. Merlin-ERM protein interactions. A. Dimerization/oligomerization with merlin
and ERM members is mediated through binding of the C-terminus of one protein to the N-
terminus of another. B. The ERM proteins and merlin are capable of intramolecular
binding through head-to-tail interactions between the C- and N-terminus. C. 3D-model of
the closed conformation of merlin. The cyan colored region shows the FERM-domain, the
purple colored region represents the α-helical domain, and the yellow colored region
represents the C-terminal domain overlaying the FERM-domain. Adapted from Sivakumar
et al. 2010193.
Although the complete structure of merlin has not been modeled, crystallographic
analysis of the FERM-domain has been conducted230,232 and it is known that also merlin is
conformationally regulated and exists in closed and open states. Similarly to the ERMs,
merlin’s self-association in the closed conformation is mediated by the binding of its C-
terminal domain to the N-terminus (Fig.9b)242,273,275,316,317, but the low level of sequence
identity between the C-terminal domains makes it unclear whether the association is
identical to that in ERM proteins. However, although the merlin C-terminus is unique, 81%
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of the residues that are conserved between merlin and the ERMs lie on the interface
between the FERM-domain and C-terminus, thereby predicting a similar conformation for
merlin150. Similarly to moesin, the merlin C-terminus folds to interact with the FERM
subdomains F2 and F3 and together with central α-helical region interactions regulate the
closed conformation193,260. Two separate intramolecular interactions mediate the closed
conformation in merlin; folding within the N-terminal domain between residues 8-121 and
200-320 and N- to C-terminal association requiring residues 302-308 and exon 17
(residues 580-595)242,317,318. Merlin isoform 2 with a variant C-terminus, as well as
mutations that remove the C-terminal exon 17 of isoform 1, form only weak intramolecular
complexes and are therefore thought to exist in constitutively open conformations242,275.
The different affinities of merlin isoforms to various interaction partners are believed to
result from their distinct conformations, as conformational changes can mask binding
sites of merlin associated proteins193.
The protein conformation is relevant for the tumor suppressor function of merlin.
Merlin is thought to modulate cell proliferation only if it is capable of forming
intramolecular associations, and in contrast to the ERMs, merlin is believed to be active
(growth suppressive) in its closed conformation242. Thus, merlin isoform 2 and molecules
with mutations in either the N- or C-terminal domain, which exhibit constitutively open
conformations, are defective as growth regulators242,318,319. However, self-association
does not seem to be required for the activity of D-merlin, as both truncated molecules and
the FERM-domain alone are fully functional in Drosophila249. Also, recent fluorescence
resonance energy transfer (FRET) studies have implicated that the conformational
regulation of merlin is more complex than just a conversion between open and closed
states260.
Although merlin predominantly exists as a stable, closed monomer260, it is also able to
form oligomers by homodimerizing and by heterodimerizing with ERM proteins (Fig.9)273-
275,318. The N- to C-ERMAD interaction of merlin is weaker and more dynamic than that of
ERMs273, and the merlin C-ERMAD forms more stable interactions with N-ERMAD of
ezrin than with its own N-terminus276. However, the heterodimerization of merlin and ezrin
requires a conformational change in both proteins273. The relevance of oligomer formation
or heterotypic interactions between merlin and ERMs is not fully elucidated, but it has
been speculated that heterodimerization could represent a mechanism to modulate the
activity of the proteins204.
6.2. Phosphorylation and phospholipid-binding
Phosphorylation, the substitution of a hydroxyl group for a phosphate group in serine,
threonine, or tyrosine residues, serves as a mechanism for regulating the activity of many
proteins. Proteins can be either activated or inactivated by phosphorylation, and it has
been estimated that approximately one-third of all cellular proteins are phosphorylated at
any given time320. The phosphorylation event can affect the protein in several ways. It can
lead to conformational changes in the substrate, or the attached phosphate group can be
recognized by interaction partners, driving the assembly of protein complexes. The
transfer of the terminal phosphate from ATP to the hydroxyl oxygen of the substrate
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residue is catalyzed by protein kinases, whereas the phosphate groups are removed in a
dephosphorylation reaction by protein phosphatases. About 2% of human genes encode
protein kinases321, and more than 500 known kinases and approximately 200 protein
phosphatases exist in the human genome322,323. Protein kinases can be classified into two
main types; serine/threonine kinases that phosphorylate their targets on serine and
threonine residues and constitute about 80% of all kinases, and tyrosine kinases that
phosphorylate their substrates on tyrosines322.
The molecular interactions and functional activities of merlin and ERM proteins are
regulated by a combination of phosphorylation and phospholipid-binding.
Phosphatidylinositol 4,5-biphosphate (PIP2) binding to the groove between subdomains
F1 and F3 in the N-terminus of ERM proteins324-326 is a major determinant of ERM
localization325, as it activates the proteins and facilitates their association with membrane
targets182,186. In addition, phospholipid-binding is required for the subsequent
phosphorylation and conformational change of ERMs327,328. Also merlin binds
phosphoinositides via a conserved motif in its FERM-domain329,330, and the phospholipid-
binding is required for membrane association, although it does not affect intramolecular
folding or phosphorylation of merlin. However, FERM-domain mediated phosphoinositide-
binding and membrane localization are critical for the growth inhibitory function of
merlin330.
Phosphorylation regulates the function of ERM proteins, and all three ERMs are
phosphorylated on serine, threonine, as well as tyrosine residues. Numerous kinases,
such as Rho kinase (ROCK)331-333, Akt334, and different protein kinase C (PKC)
isoforms313,335-337 phosphorylate a conserved C-terminal threonine (ezrin T567, radixin
T564, moesin T558). Inactive closed ERM proteins in the cytoplasm are activated by
phosphorylation at the conserved threonine, which introduces a negative charge that
reduces the affinity of the C-ERMAD for the FERM-domain in all ERMs, leading to
molecules with open conformations. These molecules are translocated to the membrane-
cytoskeleton interface, where they acquire proper conformation to bind membrane
associated molecules and actin, thus becoming functional as membrane-cytoskeleton
crosslinkers152. Besides the C-terminal threonine, ezrin is phosphorylated on several
other sites, for example on S66 by PKA338, Y145 by Lck339, EGFR340, and Src341, T235 by
Cdk5342, Y353 by Akt343 and EGFR340, and Y477 by Src344, making the regulation more
complex.
The phosphorylation status of merlin modulates cell growth arrest or proliferation, and
depends on growth conditions. Merlin is phosphorylated at low cell density, but serum
starvation, high cell density, or loss of adhesion leads to increased merlin expression and
dephosphorylation. The protein is phosphorylated on both serine and threonine residues,
but tyrosine phosphorylation has not been detected345. At least three differentially
phosphorylated forms of merlin exist, as isoform 1 migrates as three distinct bands
around 70 kDa in electrophoretic mobility assays, which are believed to reflect
differentially phosphorylated forms of the molecule247,345,346. The species with decreased
mobility is hyperphosphorylated, while the form with increased mobility is
hypophosphorylated. Merlin is phosphorylated on serine 518 (S518)247,346-348, threonine
230 (T230), and serine 315 (S315)349, but no other phosphorylation sites have been
identified. Phosphorylation or mutation of the C-terminal S518 causes a mobility shift in
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merlin and has therefore been mostly studied. The C-terminal threonine phosphorylated
in ERMs is conserved in merlin (T576), but phosphorylation at this residue has not been
detected in mammals247,350. However, in Drosophila, the Ste20 kinase Slik has been
suggested to phosphorylate merlin at the equivalent residue, T616351. Only one merlin
phosphatase has been identified, the myosin phosphatase MYPT-1-PP1-δ, which
dephosphorylates merlin at S518297.
6.2.1. PAK pathway
The activation of merlin is at least partly regulated through the Rho GTPases, as
phosphorylation of the merlin C-terminus is induced by active forms of Rac, and to a
lesser extent Cdc42, but not Rho247,348. The Rac-dependent phosphorylation at merlin
S518 is mediated by p21 activating kinases (PAKs), including PAK1 and PAK2347,348. The
PAK members include six different isoforms; PAK1-6. These proteins are serine/threonine
kinases that function as effectors for the Rho GTPases. They are recruited from the
cytoplasm to the cell membrane, where their kinase activity is stimulated by binding of
activated GTP-bound Cdc42 or Rac1 to the PAK p21-binding domain (PBD). GTPase
binding to PAK disrupts an inhibitory interaction between the kinase and autoinhibitory
domains, leading to PAK activation through phosphorylation and subsequent activation of
downstream substrates. PAKs are key modulators of not only cytoskeletal dynamics and
cell motility, but also involved in cancer-cell signaling networks and transformation352.
They promote cell proliferation and downregulate pro-apoptotic pathways leading to
tumorigenesis and cancer cell metastasis. In accordance, alterations in PAK expression
are detected in several human cancers, and both PAK1 and PAK4 are upregulated and
activated in various tumors, whereas PAK2 has both pro- and anti-apoptotic functions353.
Several cellular consequences of S518 phosphorylation are known. It directly
modulates merlin conformation as well as participates in the control of cell proliferation,
morphology and motility, all important for the ability of merlin to function as a tumor
suppressor. Phosphorylation of the merlin C-terminus weakens self-association and is
predicted to result in an unfolded, functionally inactive molecule247,350,354, although FRET
analysis have implicated that phosphorylation at S518 would lead to only subtle
conformational changes260. Besides disrupting intramolecular folding, S518
phosphorylation impairs merlin binding to the transmembrane receptor CD44255. The
S518 phosphorylated form of merlin is more soluble and relocates from the plasma
membrane to the cytoplasm as a result of decreased cytoskeletal association247,347.
Expression of a S518D mutant, mimicking the phosphorylated form, leads to dramatic
changes in both cell morphology and actin cytoskeleton organization and is unable to
suppress both motility and cell proliferation350. Thus, the hypophosphorylated, S518
unphosphorylated, presumably closed form of merlin is thought to represent the active
growth inhibitory form247,348,350. Dephosphorylation of S518 by MYPT-1-PP1δ
phosphatase is believed to activate the tumor suppressor function of merlin, leading to
growth arrest under confluent conditions297. Interestingly, the S518 residue is not
conserved among the ERM proteins, where the corresponding residue is an arginine, nor
in D-merlin, where it is a threonine350.
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Both merlin and ERMs regulate signaling via Rho GTPases by associating with Rho
regulators and effectors197,198,247,291,303. Merlin is not only downstream of Rac, but it is also
involved in modulating Rac activity302 as a negative regulator247,303. Expression of merlin
suppresses Rac-induced signaling by reducing downstream c-Jun N-terminal kinase
(JNK) and PAK1 activity, leading to the downregulation of cyclin D1 and a block of
transformation246,247,303,355. S518 dephosphorylated merlin prevents Rac recruitment to
ECM adhesions356. In addition, merlin directly suppresses PAK1 activity through binding
to PAK1 PBD and inhibits its recruitment to focal adhesions, which is required for PAK
activation303. Merlin and ERMs might also control Rho and Rac activity through their
interaction with the negative regulator Rho-GDI198,291. Although the mechanism is not
completely defined, Rac, PAK, and merlin appear to operate in a negative feedback loop,
with merlin both being regulated by the pathway and serving as an inhibitor of it. A model
for how S518 phosphorylation regulates merlin’s tumor suppressive activity in rat
schwannoma cells has been proposed. In growth permissive conditions, at low cell
density, merlin is S518 phosphorylated, growth permissive, and exists in a complex with
ezrin, moesin, and CD44. Under high cell density when cells are stimulated to undergo
growth arrest, merlin is dephosphorylated, in its closed conformation, and directly
interacts with CD44 to inhibit cell proliferation by abrogating Ras signaling255.
Merlin-deficient schwannoma cells present upregulated Rac, Cdc42, and PAK1
activity and concomitant cytoskeletal alterations138-140,247,302,303, which can be reversed by
inhibiting Rac1 or RhoA140. Many NF2-derived primary schwannomas also display highly
elevated PAK1 activity357. Activated PAK has been shown to redistribute to the leading
edges of motile cells where it stimulates both motility and invasion352. Inhibition of PAK
activity in cells lacking merlin not only restores their normal motility, but also reverses
their morphology, suppresses proliferation, and reduces their invasiveness and
tumorigenicity, suggesting that PAK activity is essential for the tumorigenesis of NF2-
deficient cells355,357,358.
6.2.2. PKA pathway
Merlin is phosphorylated on S518 also by the cyclic AMP (cAMP) -dependent protein
kinase A (PKA). PKA-mediated phosphorylation of the merlin C-terminus is detected
when PAK activity is suppressed, indicating that these two kinases function
independently to phosphorylate the same residue346. In Schwann cells, merlin is
phosphorylated on S518 through two separate pathways; by PAK as a result of ligand
binding to β1-integrin, and by PKA following ligand binding to ErbB2/ErbB3 receptors359.
Although the functional consequence of S518 phosphorylation by two distinct kinases has
not been defined, PKA-mediated phosphorylation at S518 promotes merlin-ezrin
heterodimerization346, whereas PAK2-induced S518 phosphorylation only has a weak
effect on the interaction between merlin and ezrin354.
PKA belongs to the AGC family of kinases that includes 60 members360. These
serine/threonine kinases are structurally related and have a high degree of sequence
similarity in their catalytic domains. Full kinase activity of the AGC members depends on
phosphorylation of the activation loops in their catalytic domains, but translocation to the
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plasma membrane is also essential for their optimal function361,362. Most AGC kinases
have distinct, but also overlapping substrate specificities and several of the family
members can phosphorylate the same proteins360.
PKA is a holoenzyme that in its inactive state exists as a heterotetrameric complex
consisting of two catalytic and two regulatory subunits. There are four regulatory subunit
isoforms; RIα, RIβ, RIIα, and RIIβ, and three catalytic isoforms; Cα, Cβ, and Cγ, that can 
be assembled in different combinations. Binding of the cAMP second messenger to the
regulatory subunits induces a conformational change that releases the active catalytic
subunits from the complex. PKA also requires phosphorylation of its activation segment,
either through autophosphorylation or phosphorylation by 3-phosphoinositide-dependent
kinase 1 (PDK1), to become fully functional. The released catalytic subunits are thereby
activated to phosphorylate their over 370 target substrates both in the cytoplasm and
nucleus360,363.
The targets of PKA phosphorylation are specified by their subcellular location.
Tethering of PKA to specific regions is mediated by interactions with A-kinase anchoring
proteins (AKAPs). More than 50 different PKA recruiting AKAPs have been identified,
which bind to the regulatory subunits of PKA heterotetramers thereby targeting the
enzyme to a particular intracellular site. When PKA is compartmentalized and
concentrated in proximity of its substrates, specific phosphorylation of selected proteins is
enabled364. The α-helical domain of merlin binds to the PKA regulatory subunit RIβ, and
the hypophosphorylated form of merlin has been suggested to function as an AKAP in the
CNS365. Similarly, also ezrin is both phosphorylated by PKA338 and functions as an AKAP
by binding the RIIα regulatory subunit in gastric parietal cells366,367.
The cAMP-PKA signaling pathway regulates many cellular processes including
proliferation, differentiation, apoptosis, actin cytoskeleton remodeling, and gene
transcription by modulating the activity of a variety of proteins368,369. The pathway is
altered in several cancers, and overexpression of PKA1 or changes in the relative
abundance of different PKA isoforms is a common trait of many tumors368,370. Activation of
PKA promotes cell growth and cell cycle progression also in Schwann cells371, and both
humans and mice with inactivating mutations in PRKAR1A, encoding the RIα regulatory
subunit, develop schwannomas as a result of enhanced PKA activity372,373.
6.2.3. Akt pathway
The serine/threonine kinase Akt (protein kinase B) has been shown to phosphorylate
merlin on T230 and S315 residues349. Akt is an AGC kinase family member fundamental
to many cellular processes such as motility, growth, proliferation, and apoptosis. The Akt
encoded kinase has an N-terminal PH-domain, a central catalytic domain, and a short C-
terminal regulatory domain, and the kinase family contains three isoforms; Akt1, Akt2,
and Akt3, with similar structure but some isoform-specific expression patterns. Akt1 is
ubiquitously expressed at high levels, Akt2 is mostly expressed in insulin-sensitive tissues
such as liver, skeletal muscle, and adipose tissue, whereas the highest expression of
Akt3 is detected in the brain and testis374.
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The interaction of insulin and growth factors with their cell surface receptors leads to
activation of phosphoinositide 3-kinase (PI3K) and induces the production of the
phosphatidylinositol 3,4,5-triphosphate (PIP3) second messenger at the inner surface of
the plasma membrane. Phosphorylated PIP3 recruits both Akt and PDK1 to the
membrane by binding to their PH-domains. As for many AGC kinases, activation of Akt
involves phosphorylation of two highly conserved regulatory motifs. The interaction of Akt
with phosphoinositides induces a conformational change, which enables phosphorylation
of threonine 308 (T308) in the activation segment by membrane-localized PDK1. T308
phosphorylation is necessary and sufficient for Akt activation, but additional
phosphorylation of serine 473 (S473) in the hydrophobic motif is required for maximal Akt
activity. Once activated, Akt phosphorylates its over 130 substrates at the plasma
membrane, as well as in the cytosol and nucleus360,375.
The PI3K/Akt signaling pathway is growth-promoting in many human malignancies,
and overexpression or hyper-activation of Akt plays an essential role in tumorigenesis.
Akt-mediated phosphorylation modulates the function of many important regulatory
proteins, resulting in inhibition of apoptosis and increased cell division, this way
promoting cell survival. Both upstream components of the Akt pathway such as PI3K, and
phosphatase and tensin homologue deleted on chromosome 10 (PTEN) as well as
downstream effectors like forkhead box O (FOXO), glycogen synthase kinase 3β
(GSK3β), and tuberous sclerosis complex (TSC)1/TSC2-mammalian target of rapamycin
(mTOR) are deregulated in malignant tumors376,377. PTEN, that antagonizes PI3K activity,
is a major negative regulator of Akt activation and the second most commonly mutated
tumor suppressor in humans. The pathway is also one of the most frequently targeted
signaling routes in sporadic tumors, with estimates that alterations in PI3K pathway
components could account for up to 30% of all human cancers378.
Activation of the Akt pathway has also been implicated in Schwann cell survival,
differentiation, and proliferation379-382, and several studies indicate an interplay between
merlin and Akt. The Akt pathway is activated in both human schwannoma304,383,384 and
malignant mesotheliomas from heterozygous Nf2+/- mice385. Merlin controls the PI3K/Akt
pathway by inhibiting Akt signaling244,300. It suppresses PI3K activity by binding to PI3K
enhancer long isoform (PIKE-L), preventing its association with PI3K300. Not only merlin,
but also ezrin regulates the pathway by activating PI3K leading to increased Akt
phosphorylation and enhanced cell survival343. Akt-mediated phosphorylation of T230 and
S315 residues has been described to attenuate the intramolecular folding of merlin, to
inhibit its association with PIKE-L, CD44, and ezrin, and to result in merlin degradation.
Expression of a phosphomimetic T230D+S315D mutant increases cell motility and
proliferation, whereas the T230A+S315A mutant has the opposite effect349. Also
apoptosis decreases markedly with the phosphomimetic mutant compared to WT,
similarly to cotransfection of active Akt and WT merlin329.
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Figure 10. Cross-talk between the PI3K/Akt, PAK, and PKA pathways.
The intracellular signaling pathways that are involved in phosphorylating merlin are
crosslinked (Fig.10), making phosphorylation-mediated regulation of merlin a complex
process. The signaling routes not only interact, but the different kinases can enhance and
in some situations also inhibit the activation of another signal transduction pathway. Rac
is a downstream target of PI3K, but Rac can also stimulate the activation of PI3K386. Rac
also regulates Akt through PAK387. The PI3K effector PDK1 activates not only AGC
kinases Akt and PKA, but also PAK388. In addition, PAK can be stimulated directly
through PI3K or indirectly via Akt phosphorylation389, as Akt phosphorylates and activates
PAK390. A cross-talk between PKA and PAK also exists where PKA negatively regulates
PAK through phosphorylation391.
6.3. Protein stability and the ubiquitin proteasome pathway
In addition to a protein’s expression level and post-translational modifications, protein
activity is regulated by its turnover rate. Eukaryotic cells contain two major protein
destruction pathways; the proteasomal pathway and the lysosomal apparatus. The
lysosome with proteolytic enzymes plays a minor role in the turnover of cytosolic proteins
as it primarily degrades membrane-associated or endocytosed extracellular proteins.
Most intracellular proteins are degraded by the ubiquitin-proteasome pathway (UPP),
which recognizes and eliminates misfolded and abnormal molecules by proteolysis, but
also functions in protein turnover. By selectively degrading proteins whose concentrations
quickly must vary in response to different cell states, it reduces protein lifetimes and is
able to rapidly turn off the effect of its target substrate. The selective and controlled
proteolysis of proteins by UPP has an essential regulatory role in a variety of cellular
processes, including cell-cycle progression and proliferation, signal transduction,
transcriptional regulation, differentiation, angiogenesis, apoptosis, and protein quality
control392.
In the UPP, proteins are targeted for degradation by attachment of ubiquitin
molecules, highly conserved small proteins composed of 76 amino acids. In the process
of ubiquitination, the C-terminus of the ubiquitin molecule is covalently linked to lysine
residues in target substrates through the coordinated function of several enzymes. In the
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first step of the cascade, ubiquitin is activated by an E1 ubiquitin-activating enzyme.
Following activation, ubiquitin is transferred to an E2 ubiquitin-conjugating enzyme, which
associates with an E3 ubiquitin ligase capable of recognizing a specific target protein to
be ubiquitinated. E2 facilitates the transfer of activated ubiquitin to the E3 ligase-protein
complex, and the E3 ligase catalyzes the attachment of ubiquitin to the target protein.
When the protein is tagged with a single ubiquitin; mono-ubiquitinated, it signals to attach
additional ubiquitin molecules to form a polyubiquitin chain marking the protein for
degradation392. The polyubiquitin chain usually consists of at least four ubiquitin
monomers and is formed through the same ubiquitination cascade with the facilitation of
E4 chain elongation enzymes393.
Polyubiquitination directs the protein to the proteasome complex for degradation. The
proteasome is a large multicatalytic protease complex located in both the nucleus and
cytoplasm of cells. The cylindrically shaped 26S proteasome is composed of a 20S
catalytic core subunit, in which proteins are degraded, with one or two 19S regulatory
subunits at either or both ends. The polyubiquitin chain on the target protein is recognized
by ubiquitin receptors in the 19S complex, the chain is cleaved off the substrate, and the
ubiquitin monomers are released by deubiquitination enzymes and recycled for future
use. The target protein is then unfolded, inserted into the lumen of the 20S proteasome
complex, and degraded by its proteolytic activity into short peptides of 3-20 residues,
which can be further cleaved into amino acids and used in the synthesis of new
proteins392,394. Some proteins can also be degraded by the 26S proteasome without
ubiquitination395.
To prevent the random destruction of proteins, ubiquitination is tightly controlled.
There are about 50 E2 enzymes, and more than 500 different E3 ligases. Distinct E3
proteins or E2-E3 complexes recognize specific degradation signals in their substrates
allowing for selective tagging and thereby conferring high specificity for degradation.
Some substrates contain constitutively active degradation signals, whereas other proteins
require a post-translational modification of their sequence motif. A common way to
activate a degradation signal on the target protein is by phosphorylation of specific sites,
leading to the exposure of a normally hidden degradation motif. Different ubiquitin ligases
are able to recognize distinct phosphorylation patterns in their target substrates. Hence,
the specificity of UPP is increased by both post-translational substrate modifications and
by regulation of the intracellular compartmentalization of the substrate and its E3
ligase392,394,396.
Besides targeting proteins for destruction, different ubiquitin modifications function as
regulatory cellular signals. Instead of a polyubiquitin chain, ubiquitin can be conjugated to
target proteins as a monomer (monoubiquitination), as multiple monoubiquitins
(multiubiquitination), or as short ubiquitin chains. The amount of attached ubiquitin
molecules determines how the signal is interpretended and where the protein is targeted.
Monoubiquitination regulates the activity and subcellular localization of diverse
proteins397, but ubiquitin conjugates also affect intermolecular interactions, as many
proteins contain ubiquitin-binding domains that recognize and distinguish different types
of ubiquitin modifications398.
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6.3.1. Degradation of merlin
Several reports have demonstrated a link between merlin and the UPP. Both full-length
missense mutants and N-terminally deleted molecules of merlin show an increase in
ubiquitination and are degraded by the UPP284,399, indicating that the pathway is important
in eliminating abnormal merlin products. Wild-type merlin is more stable, but also found
ubiquitinated when overexpressed399. As the mRNA expression levels of missense merlin
mutants in NF2-associated tumors is unchanged in spite of their reduced protein
expression, loss of function of the proteins has been suggested to result from a decrease
in mutant protein half-life and increased degradation rather than from their abnormal
function284.
Akt-induced phosphorylation promotes polyubiquitination and proteasome-mediated
degradation of merlin349. In some cellular systems, merlin is targeted to the Roc1-Cul4-
DDB1 E3 ligase complex through the WD40-containing adaptor protein VprBP/DCAF1
(DDB1- and Cul4-associated factor 1). Binding of merlin to the complex affects its stability
by inducing polyubiquitination and consequent degradation through the proteasome400.
However, another study suggested that rather than serving as a substrate, the closed
form of merlin translocates to the nucleus where it binds to E3 ubiquitin ligase CRL4DCAF1,
and inhibits its activity to mediate ubiquitination of other target proteins261. NGB (NF2-
associated GTP binding protein) has been shown to regulate the turnover of merlin by
decreasing its ubiquitination, this way preventing degradation401. Moreover
spectrin266,402,403, that possesses both E2 and E3 activities404, and the cell cycle regulator
human enhancer of invasion clone 10 (HEI10)405, which can function as an E3 ubiquitin
ligase406, interact with merlin, so merlin ubiquitination could be mediated through several
of its binding partners.
The F1 motif of merlin FERM-domain contains an ubiquitin-like structure that can
stimulate ubiquitination and proteasomal degradation of other proteins150,230,232.
Accordingly, the FERM-domain of merlin has been shown to facilitate the degradation of
the p53 negative regulator Mdm2 which is an E3 ubiquitin ligase407, and to induce the
ubiquitination and degradation of TRBP, a double-stranded RNA-binding protein with
growth-promoting activity408. Thus, merlin both serves as a substrate for the UPP
pathway and acts to enhance the degradation of other proteins.
Also calpain-mediated proteolysis of merlin has been described. Calpains are a family
of calcium-dependent cysteine proteinases that catalyze the proteolysis of many
substrates, and their expression is often altered during tumorigenesis409. Merlin is cleaved
by calpain, and NF2-associated tumors display activation of the calpain system
suggested to result in loss of merlin expression410.
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AIMS OF THE STUDY
This study was undertaken to gain further insight into the function of the NF2 tumor
suppressor protein merlin. Since merlin and the homologous ERM protein ezrin have
opposite proliferative effects, we hypothesized that the regions which differ between the
proteins might explain merlin’s specificity as a tumor suppressor. The first 18 residues of
merlin are unique and have no equivalents within the ERM proteins, and the C-terminus
is the domain least conserved between the family members with a homology of only 22%
between merlin and ezrin. Therefore, the aim of this study was to characterize the impact
of these regions on merlin’s cellular and molecular properties. We were particularly
interested in analyzing the impact on cytoskeletal organization, phosphorylation, and
growth inhibition.
The specific aims set for this study were:
(1) to characterize the N-terminal phosphorylation of merlin and to evaluate its
functional consequence
(2) to analyze the functional differences between merlin isoforms 1 and 2
(3) to examine the morphogenic properties of merlin and to identify C-terminal
regions required for this activity
(4) to determine the effect of merlin’s C-terminal region on growth inhibition
(5) to define the importance of the conserved C-terminal motif E545-E547, not
present in the ERMs
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MATERIALS AND METHODS
The materials and methods used are described in more detail in the original publications.
1. Materials
1.1. Cell lines (I, II, III)
293 human embryonic kidney (HEK) cells were cultured in RPMI 1640 medium
supplemented with 10% fetal bovine/calf serum (FBS/FCS) (PromoCell) and antibiotics.
Monkey kidney fibroblasts (COS-7 cells), mouse embryonic fibroblasts (MEFs), Nf2-/-
MEFs, and ezrin-/- MEFs were all maintained in DMEM (Gibco-Invitrogen) with 10%
FBS/FCS and antibiotics. Primary Nf2 knockout Schwann cells68 were isolated and
cultured as previously described411 and used before passage 20. All cells were cultured at
+37°C in a 5% CO2 humified incubator.
1.2. Antibodies (I, II, III)
Anti-merlin A-19 sc-331 polyclonal antibody (pAb), C-18 sc-332 pAb (both from Santa
Cruz Biotechnology), and KF10 monoclonal antibody (mAb)282 were used to detect
merlin. S518 phosphorylated merlin was detected with pS518 pAb (Biodesign). Rabbit
pAb recognizing human merlin phosphorylated on S10 was produced by immunization of
a 11-mer synthetic phosphopeptide IASRM(pS)FSSLK and subsequent purification of the
antiserum using both negative and positive affinity purification methods. The specificity of
the antibody was tested against in vitro Akt phosphorylated GST-merlin with and without
S10A mutations. Ezrin was detected with 3C12 mAb412. Alexa-568 conjugated phalloidin
(Invitrogen-Molecular Probes) was used to stain F-actin, α-tubulin mAb (Sigma-Aldrich) to
detect tubulin, and anti-GST pAb (GE Healthcare) to detect glutathione S-transferase
(GST)-proteins. Pan-Akt and phospho-Ser473 Akt pAbs (both from Cell Signaling
Technology) were used for Akt detection, phospho-GSK3α/β (Ser21/9) (Cell Signaling
Technology) and GSK3α (Santa Cruz Biotechnology) antibodies for GSK3 detection, and
anti-VprBP pAb (SMS-Gruppen) for DCAF1 detection. For detection of ubiquitin, Ub
(P4G7) (Santa Cruz Biotechnology) was used. Ki-67 mAb sc-7846 (Santa Cruz
Biotechnology) was used as a marker of cell proliferation, and the nuclei were stained
with TO-PRO 3-iodide probe (Molecular Probes). Alexa-488-, Alexa-568- and Alexa-594-
conjugated goat anti-mouse and goat anti-rabbit antibodies (Invitrogen-Molecular Probes)
were used as secondary antibodies in immunofluorescence, and HRP-conjugated rabbit
anti-mouse, swine anti-rabbit (both from DAKO A/S), and swine anti-goat (Santa Cruz
Biotechnology) secondary antibodies in western blot analysis.
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1.3. Constructs and samples (I, II, III)
Human merlin isoform 1 (WT, sequence coding for amino acids 1-595) and isoform 2
(sequence coding for amino acids 1-590) in pcDNA3 vector (Invitrogen) were used for
transfection experiments of full-length proteins. C-terminally truncated constructs 1-587,
1-569, 1-547, 1-537, and 1-518 were created from merlin isoform 1 by digestion with
restriction endonucleases and ligation into the pCDNA3 vector. For expression of
recombinant GST-fusion proteins, the following constructs were used: merlin 1-100,
merlin N-terminus (1-314), merlin α-helix (314-477), merlin 1-547, merlin C-terminus
(492-595), and full-length ezrin, all in pGEX4T1 vector (Amersham Biosciences). Point
mutations of merlin in all vectors were made by site-directed mutagenesis using the
QuikChange Kit (Stratagene). The Δ2 merlin construct with a deletion of residues 50-70
in exon 2 has been described before277. WT or S518A merlin in pDEST27 vector
(Invitrogen) containing an N-terminal GST-tag was used for metabolic labeling, and merlin
retro- and adenovirus constructs have been previously described243,270. Akt WT in
pUSEamp vector was from Upstate Biotechnology, and the cDNAs of the myristoylated
Akt and myristoylated kinase dead K179A Akt were obtained from Dr. Rene H. Medema.
DCAF1 in pRK5 vector was obtained from Dr. Filippo Giancotti and has been previously
described261. GFP in pCDNA3 vector was used as control in proliferation assays. Both the
c-Ha-Ras C61L construct (Addgene plasmid 13485)413 used in soft agar experiments and
GFP-α-actinin414 used in live cell imaging have been described before.
The frozen tumor material was obtained from the Neurofibromatosis Clinic of
Massachusetts General Hospital, and contains a 1646 delT mutation in the NF2 gene and
LOH compared to the matching blood sample283.
2. Methods
2.1. Cell transfections and treatments (I, II, III)
Cells were transiently transfected using FuGENE6 reagent (Hoffmann-La Roche) or
Lipofectamine 2000 (Invitrogen) for Schwann cells, and incubated for 48 h before
analysis.
For Akt kinase activation and inhibition experiments, cells were cultured in serum-free
medium for 24 h and treated before lysis with 0.2 μg/ml human recombinant epidermal
growth factor (EGF) (Calbiochem) for 10 min, with 50 μM LY-294002 (Sigma-Aldrich) for
1 h, or with 0.1 μM Calyculin A (Calbiochem) for 10 min all at +37°C. For degradation
assays, serum starved cells were treated for 24 h with 5 μM MG132 or 0.1 μM
Bafilomycin A1 (both from Sigma-Aldrich). To activate or inhibit PKA activity, cells were
treated with 50 mM IBMX and 25 mM forskolin or 10μM H89 (all from Sigma-Aldrich) for
24 h.
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2.2. Immunofluorescence and immunoblotting (I, II, III)
For immunofluorescence, cells grown on glass coverslips were fixed in 3.5%
paraformaldehyde (pH 7.5) in +4°C for 15 min followed by washes with phosphate
buffered saline (PBS). The cells were permeabilized with Triton X-100, detected with
appropriate antibodies using standard protocols, and imagined with a fluorescence
microscope equipped with an Axiocam cooled CCD camera (Carl Zeiss).
For the Latrunculin B assay, Nf2-/- MEFs were fixed 48 h after transfection (zero
timepoint) or treated with 2.5 mM Latrunculin B (Sigma-Aldrich) for 8 min. Cells were
stained for merlin and phalloidin and analyzed with a fluorescence microscope.
For western blotting, cells were rinsed with PBS and lysed in ELB buffer (50 mM
HEPES pH 7.4, 150 mM NaCl, 5 mM EDTA) containing 0.5% Nonidet P-40 (NP-40),
HALT phosphatase inhibitors (Pierce), and Complete protease inhibitors (Roche). Lysed
cells were centrifuged at 13 000-20 000 g for 20-30 min at +4°C. The pellet (insoluble)
and supernatant (soluble) were resolved in equal amounts of reducing Laemmli buffer.
Protein concentrations were determined by Bio-Rad Protein Assay (Bio-Rad) when
needed. Whole cell lysates were prepared by adding reducing Laemmli sample buffer on
the culture plates. The tumor sample was dissolved in reducing Laemmli and sonicated.
Samples were resolved in 8-12% sodium dodecyl sulphate-polyacrylamide gel
electrophoresis (SDS-PAGE), transferred to nitrocellulose filters, and analyzed by
immunoblotting with appropriate antibodies using enhanced chemiluminescence (ECL)
detection (Amersham-Biosciences).
2.3. Immunoprecipitations (II)
COS-7 cells were lysed 48 h after transfection in ELB buffer containing 0.5% NP-40,
HALT phosphatase inhibitors and Complete protease inhibitors. Lysed cells were
centrifuged at 13 000 g for 20-30 min at +4°C. The supernatants were diluted 1:1 to ELB-
buffer without NP-40, and precleared with glutathione (G)-sepharose beads (Amersham
Biosciences) for 1 h at +4°C. Beads were spun down, and cleared supernatants were
incubated with appropriate antibodies overnight at +4°C under rotation. G-Sepharose
beads were added and the samples were incubated for additional 4 h at +4°C under
rotation. Immunoprecipitates were washed with ELB buffer, and bound proteins were
eluted from the beads by boiling in non-reducing Laemmli buffer and analyzed by
immunoblotting.
2.4. Metabolic labeling (I)
48 h after GST-merlin transfection 293 HEK cells were changed into serum- and
phosphate free DMEM, and 1 mCi/ml of 32P labeled orthophoshate (Amersham
Biosciences) was added for 2 h. Cells were treated with 50 µM IBMX and 25 µM forskolin
or 40 µM H89 for 30 min or 2 h, respectively. Cells were lysed in ELB-buffer with 1% NP-
40, phosphatase inhibitors (HALT, 1.5 µM Calyculin A (Calbiochem), Cocktail Set IV
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(Calbiochem), 1.5 µM okadaic acid), and protease inhibitors, and centrifuged at 14 000 g
for 30 min at +4˚C. Samples were diluted to a final concentration of 0.5% NP-40, G-
sepharose was added to the lysates, and the samples were incubated over night at +4˚C.
Beads were washed with ELB-buffer containing inhibitors, reducing Laemmli buffer was
added, and samples were run in SDS-PAGE. Gels were silver stained following standard
protocol, dried and exposed on a PhosphoImager plate, read by TyphoonImager 9400,
and analyzed by ImageQuant TL2003 software (all by GE Healthcare).
2.5. In vitro phosphorylation assays (I, II)
GST-fusion proteins were expressed in E. coli DH5α and purified. G-sepharose beads to
which ~4 µg of fusion protein was conjugated were washed in PKA buffer (20 mM Tris-
HCl, 10 mM MgCl2 pH 7.4), Akt buffer (50 mM Tris-HCl pH 7.5, 0.1 mM EGTA, 15 mM
DTT, 15 mM MgCl2, 100 μM ATP), or PKC buffer (1/5 PKC lipid activator (Upstate
Biotechnology), 20 mM HEPES, 10 mM MgCl2, 0.1 mM EGTA, 500 μM ATP) containing
Complete protease inhibitors. Phosphorylation reactions were carried out in a 30 µl buffer
volume including 10 µCi of [γ-33P] ATP (PerkinElmer Life Sciences) and 2 ng of purified
human recombinant PKA (Sigma-Aldrich), 0.1 μg of human recombinant active Akt1
(ΔPH, S473D), Akt 2 (δPH, S474D), or Akt3 (117-end, S472D) (Upstate Biotechnology),
or 5 ng of human recombinant PKCθ (Invitrogen) for 30 min at +30°C. Beads were
washed in kinase buffer, reducing Laemmli buffer was added, and samples were resolved
by SDS-PAGE. The gel was fixed and stained by Coomassie Blue followed by exposure
on PhosphoImager plate and detection with Typhoon Imager 9400.
For Akt in vitro kinase assays of the full-length protein, COS-7 cells were transfected
with merlin constructs and expressed proteins were immunoprecipitated with the C-
terminal merlin KF10 mAb. Immunoprecipitated proteins were phosphorylated in vitro by
Akt1 as described above.
2.6. Affinity pull-down (I, II, III)
Transfected COS-7 cells were lysed in cold binding buffer 1 (50mM HEPES pH 7.4, 150
mM NaCl, protease inhibitors) or binding buffer 2 (140 mM NaCl, 1 mM Tris pH 7.5)
containing 0.5% Triton X-100 and Complete protease inhibitors, and the homogenates
were cleared by centrifugation at +4°C for 20 min at 13 000 g. GST-merlin and ezrin
fusion proteins were bacterially expressed and purified. G-sepharose beads carrying ~4
µg of proteins were washed in binding buffer and incubated with the lysates under
rotation over night at +4°C. Samples were washed with binding buffer, reducing Laemmli
buffer was added, and bound proteins were separated by SDS-PAGE. Proteins were
detected with appropriate antibodies.
For the pull-down of phosphorylated merlin, G-sepharose beads carrying ~5 μg of
merlin fusion protein were washed in PKA buffer and phosphorylated by human
recombinant PKA as described above except that 200 µM of cold ATP (Sigma-Aldrich)
was used in the reaction. After phosphorylation beads were washed in binding buffer 1.
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Bacterially expressed full-length ezrin was cleaved from GST by thrombin (Sigma-
Aldrich), and ~4 µg of ezrin was incubated with phosphorylated or unphosphorylated
merlin constructs under rotation for 2 h at +4˚C. Beads were washed with binding buffer,
reducing Laemmli buffer was added, bound proteins were resolved in SDS-PAGE, and
proteins were detected with ezrin and GST-antibodies.
2.7. In vitro wound-healing assay (I)
Nf2-/- MEFs and Nf2-/- Schwann cells (P18) were infected with retro- and adenovirus
constructs, respectively, containing merlin or empty virus as previously described243,270.
Plates were wounded 24-48 h after infection, and the wound-healing was monitored. After
72 h, cells were fixed and stained with merlin to control infection efficiency. Quantification
of wound width was done by ImageJ (v10.2) image processing software.
2.8. Live cell imaging (I, III)
Nf2-/- MEFs, grown on LabTek glass chamber slides (Nunc), were cotransfected with
GFP-α-actinin and merlin 24-48 h prior to imaging. Live cells expressing merlin were
chosen by their GFP expression and imaged with an inverted Olympus IX81 microscope
and CellR program at +37˚C, 5% CO2. Images were taken once every 30 seconds for 5 h.
GFP-expression images were taken before and after the experiment, and the cells were
stained for merlin to verify expression.
2.9. Soft agar colony assay and proliferation analysis (III)
For soft agar colony formation assay, Nf2-/- MEFs were transfected with c-Ha-Ras C61L
CMV together with merlin constructs or empty pcDNA3 vector. 48 h after transfection 5 x
104 cells were plated in triplicates in 0.3% agar containing DMEM and 10% FBS on a
layer of precast 0.6% agar. After 2-3 weeks of growing in soft agar cells were stained by
0.005% Crystal Violet for 2-3 h. Plates were scanned and the number of the colonies on
each plate was determined by count from three independent experiments.
For the proliferation assay, Nf2-/- MEFs transfected with merlin or GFP as a control
were first serum starved followed by serum treatment for ~12 h. Cells were stained for
merlin and the proliferation marker Ki-67. Ki-67 positivity from 400 cells of each construct
from four independent experiments was quantified.
2.10. Quantifications and image analysis (I, II, III)
For quantification of actin, Nf2-/- MEFs transfected with merlin constructs were stained for
merlin and with phalloidin. Cells were imaged with immunofluorescence microscopy using
a fixed exposure of 900 ms for phalloidin. The intensity of the actin staining was
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measured from whole cells by Image J software. Total fluorescence from twenty merlin
transfected cells and untransfected cells from the same slides were analyzed separately,
and the staining intensities were normalized to untransfected cells.
For quantification of cell-extensions, transfected Nf2-/- and ezrin-/- MEFs were stained
for merlin and untransfected Nf2-/- MEFs for ezrin or phalloidin for ezrin-/- MEFs. Cells
were imaged with fluorescence microscope and the extension length was measured from
twenty untransfected cells and cells expressing the different constructs. The total length
of all extensions from each cell was quantified and the mean length per cell calculated.
ImageQuant TL2003 software was used to analyze band intensities from
immunoblots. Merlin intensities were normalized to tubulin to obtain the merlin/tubulin
ratio, or the p-S518 amount to total merlin to obtain the p-S518/merlin ratio. For
quantification of phosphorylation, the phospho-signal from the autoradiograph read by
TyphoonImager 9400 was analyzed by ImageQuant TL2003 and normalized to the
Coomassie-staining, and the background radioactivity (untransfected cells or empty GST
plasmid) was subtracted from merlin samples.
Images of 293 cells transfected with WT merlin, taken with the Axiocam cooled CCD
camera, were analyzed with the ImageJ software. Rectangular sections from the cell
body towards extensions were chosen from the images, and pixel intensities were
calculated for both the staining of transfected merlin and the endogenous ezrin.
All quantifications were done from at least three independent experiments and
student’s t-test was used for calculation of P values.
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RESULTS AND DISCUSSION
1. Merlin serine 10 is phosphorylated by both PKA and AKT (I, II)
Phosphorylation serves as a mechanism to regulate the tumor suppressive activity of
merlin. Both the N- and C-terminal halves of the protein contain phosphorylated
residues247, and previous mass spectrometry analysis has shown that all four serines
present in the N-terminal extended tail (S7, S10, S12, and S13) can be
phosphorylated415. Our earlier studies indicated that the N-terminus of merlin is
phosphorylated in response to active PKA346, and we therefore wanted to further
characterize this phosphorylation. To determine the N-terminal phosphorylation site, the
substrate residue was first mapped to the 100 most N-terminal amino acids of merlin by
an in vitro PKA phosphorylation assay using truncated proteins, and then all potential
kinase recognition motifs in this region were mutated to non-phosphorylatable alanines.
Mutation of serine 10 (S10) abrogated PKA-mediated merlin phosphorylation, thus
identifying the residue as a phosphorylation site in vitro (I, Fig.1c). In addition, mutation of
both S10 and the previously identified C-terminal S518 in the same construct showed that
these two amino acids represent the only PKA substrate residues in merlin (I, Fig.1d).
PKA-mediated phosphorylation of merlin S10 was also confirmed by metabolic labeling,
which demonstrated that activation of PKA leads to an increase in the phospho-signal
despite the S518A mutation (I, Fig.1b). Thus, merlin S10 functions as a PKA
phosphorylation site both in vitro and in vivo. Although S518 serves as a substrate
residue for both PAK and PKA, S10 is probably not phosphorylated in response to PAK
as activated Rac induces phosphorylation of only the merlin C-terminus247.
A connection between merlin and Akt signaling has been described, and we therefore
wanted to study also the Akt-mediated phosphorylation of merlin. Surprisingly, S10 was
identified as not only a PKA site, but also as an Akt substrate residue by in vitro kinase
assays of both merlin fragments and the full-length protein (II, Fig.1a and Fig.1c). The Akt
dependent phosphorylation of merlin S10 was confirmed also in vivo by mass
spectrometry analysis. Although earlier studies suggested that T230 and S315 would
serve as Akt phosphorylation sites in merlin349, we could not detect phosphorylation of
these residues in vitro with any of the three Akt isoforms (II, Fig.1e). We also generated
an antibody against phospho-S10 to specifically recognize the phosphorylated residue,
but the affinity of the phospho-specific antibody was not sufficient to detect endogenous
S10 phosphorylated merlin, even though the antibody showed specific reactivity against
in vitro phosphorylated GST-merlin (II, Fig.1d).
The region around S10 (Fig.11) corresponds to the known PKA recognition motif R-X-
S/T (where X denotes any amino acid)416. However, the motif is unique as an Akt
phosphorylation site, since the preferred consensus sequence R-X-R-X-X-S/T contains
arginines at positions -3 and -5417,418, which are not present in merlin. However, authentic
phosphorylation sites do not always conform to the consensus motifs322, and many AGC-
kinase substrate proteins are phosphorylated on non-optimal sequences, probably
because they have other motifs that give the specificity for the interaction360.
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Figure 11. The sequence around serine 10. Consensus phosphorylation motifs for Akt
and PKA are shown above the human merlin N-terminal tail sequence (amino acids 1-
18). Serine 10 is underlined in the sequence. The corresponding region of merlin proteins
from several species is shown below. Alignment adapted from Golovnina et al. 200558.
We mapped the Akt binding site of merlin to reside between N-terminal residues 100-
314 (II, Fig.2b), and concluded that the interaction was not dependent on the
phosphorylation state of S10 (II, Fig.2a and Fig.2c). Similarly, the binding motif of the
PKA regulatory subunit RIβ is located in the α-helical part of merlin365, whereas the PKA
phosphorylation site is present at the C-terminus346. Docking motifs, the interaction
domains between the kinase and its substrate, provide an additional mechanism for
substrate recognition of serine/threonine kinases419, and function to enhance substrate
specificity by increasing the affinity of the kinase for its substrate322,420. It is common that
these docking motifs are distinct and often remote from the phosphorylation site419,420.
Thus, residues between 100-314 might comprise a docking motif that allows
phosphorylation of the suboptimal S10 sequence by Akt.
The AGC kinases have similar substrate preferences360 and there are many examples
of these kinases phosphorylating the same proteins. For example the N-terminal serine
S21/9 residue in GSK3α/β is phosphorylated by at least five members of the AGC
family421. The ability of different kinases to phosphorylate the same substrates has
probably evolved to allow different extracellular stimuli to regulate similar cellular
responses360. Likewise, S518 is phosphorylated by both PKA and PAK in response to
distinct extracellular signals, neuregulin-1β for PKA and laminin-1 for PAK359. As both
PKA and Akt phosphorylate merlin on S10, we wanted to test whether the residue serves
as a substrate motif for also other members of the AGC kinase family. Therefore, an in
vitro kinase assay was conducted with PKCθ, another AGC member which has not been
described as a merlin phosphorylating kinase, but phosphorylates ezrin313,337. Our assays
showed that PKC phosphorylated the merlin N-terminus (residues 1-314), but the S10A
mutation had no effect on the reaction (II, Fig.1b), confirming that S10 represents a
specific PKA and Akt phosphorylation site. This was further verified by Tang et al.349, who
showed that AGC kinases p70S6K and p90RSK are unable to phosphorylate merlin. As the
binding motifs for PKA and Akt are distinct despite the same N-terminal phosphorylation
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site, the different docking motifs of the kinases might provide for the regulation of N-
terminal merlin phosphorylation.
Taken together, we identify a novel phosphorylation site, S10, in merlin, and confirm
that PKA, Akt, and PKC function as kinases phosphorylating the merlin N-terminus
(Fig.12). The phosphatase dephosphorylating merlin at S10 remains to be discovered.
Figure 12. Merlin phosphorylation sites. Merlin is phosphorylated on S10 in response
to both Akt and PKA, and on S518 by PKA and PAK. The previously identified Akt
phosphorylation sites T230 and S315 could not be confirmed in this study. PKC
phosphorylates the merlin N-terminus (1-314), but not S10.
2. Functional effects of S10 phosphorylation (I, II)
The identified PKA and Akt phosphorylation site, S10, resides in the N-terminal extended
tail region that is excluded from the FERM-domain230-232, and which is not conserved in
the ERMs. The tail is, however, present in merlin proteins of various species58, and S10 is
conserved in merlin orthologs of for example mouse, chicken, zebrafish, and Xenopus
(Fig.11), suggesting that the residue has important functions. However, it should be noted
that Drosophila merlin lacks the first 9 N-terminal residues, and does not contain S10.
The N-terminal extension of merlin has been shown to be necessary, although not
sufficient, for contact-dependent inhibition of proliferation415, so modifications on S10
could therefore have a large impact on merlin activity. Phosphorylation studies with merlin
are challenging to conduct as endogenous merlin expression is very low in most cell lines
and subtle changes in phosphorylation of a subfraction of molecules cannot be detected.
We therefore took a mutational approach using transfected phosphomimetic S10D and
non-phosphorylatable S10A merlin constructs to characterize the functional
consequences of S10 phosphorylation.
When S10 mutants were transfected into fibroblasts, they induced apparent
morphological changes. Expression of merlin S10A resulted in long cellular extensions
whereas S10D expression induced a morphology with dense filopodia-like structures (I,
Fig.2c and Fig.3). The 18 most N-terminal residues of merlin are involved in actin
binding231 and necessary for association with the cortical cytoskeleton415. We therefore
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hypothesized that merlin S10 phosphorylation influences cell morphology through its
effect on actin. Accordingly, the results showed that the phosphorylation status of S10
regulated actin cytoskeleton organization. The actin network at the cytoskeleton-
membrane interphase and the amount of F-actin stress fibers were both affected by S10
mutations (I, Fig.4 and Fig.5). Merlin stabilizes actin filaments through lateral association
and by slowing their depolymerization272, and our assays indicate that the
phosphorylation status of S10 has an impact on merlin’s ability to regulate F-actin
organization. It has been suggested that phosphorylation of the N-terminal tail would also
regulate the targeting of merlin to the plasma membrane415, but both S10A and S10D
constructs localized similarly to WT beneath the membrane (I, Fig.3). However, targeting
may be regulated by phosphorylation of other N-terminal tail residues.
Since we observed changes in both the morphology and actin organization of cells
expressing S10 mutants, we analyzed the effect of S10 on cell motility by wound-healing
assays and live cell imaging. Merlin has an inhibitory effect on cell motility285,286, and Nf2-
deficient MEFs migrate in wound-healing assays faster than their merlin expressing
counterparts247. This was observed also in our studies with both MEFs and Schwann
cells, but interestingly, S10A merlin expressing cells migrated even slower than the WT
merlin infected cells (I, Fig.6a). PKA is present at the leading edge during cell migration422
similarly to merlin, so their interaction could lead to S10 phosphorylation in motile cells.
Lamellipodia localizes the protein complexes that drive the actin polymerization required
for cell motility125. S10A expressing cells displayed altered lamellipodia formation as
observed by live cell imaging (I, Fig.6b), possibly explaining the reduced ability of S10
mutants to migrate in wound-healing assays. Altogether, these results show that
regulation of the merlin S10 phosphorylation state is critical for cell motility.
The detected effect of S10 mutants during cell migration probably reflects the role of
merlin in cytoskeletal remodeling, since the S10A mutant, blocked in an
unphosphorylated state, disturbs merlin’s normal regulative effect on the actin
cytoskeleton, lamellipodia formation, and migration. We hypothesize that this is due to a
different mechanism than direct actin association since the S10 mutants did not affect
actin binding or depolymerization compared to the WT protein in our in vitro assays.
Merlin has several binding partners that are able to modulate the actin cytoskeleton262,
and the regulatory effect of merlin on actin organization could be mediated through these
interacting proteins. It has been proposed that the N-terminal tail, containing S10, serves
as a common protein-binding motif58, and the region is required at least for the interaction
with the schwannomin interacting protein-1 (SCHIP-1)423. The extreme N-terminal
residues could form a flexible tail that participates in the regulation of binding to
interaction partners, depending on its phosphorylation status.
Our studies indicate that phosphorylation of S10 can also direct the protein for
degradation, thereby down-regulating merlin stability and function. The effect was
observed when active membrane-bound Akt was coexpressed with WT merlin, whereas
degradation of the S10A mutant was significantly reduced (II, Fig.3a). The degradation is
mediated by the proteasome, as the proteasomal inhibitor MG132 increased the amount
of merlin in cells expressing active Akt (II, Fig.3c). Several studies have shown that
inhibition of proteasomes does not increase the cellular level of merlin261,349,399,410, and the
protein exhibits a half-life of more than 24 hours in many cell types261. It is possible that
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efficient and fast proteasomal degradation of merlin requires a prior post-translational
modification, such as phosphorylation of S10 at a specific subcellular localization, to
reduce the protein half-life when its growth inhibitory activity is not needed in non-
confluent cells. Phosphorylation could this way provide an additional level of control to
merlin degradation, as the initial regulatory event would be carried out by the specific
kinase, while the E3 ubiquitin ligase would then recognize only the phosphorylated form
of the protein.
Previous studies demonstrated that merlin associates with the DCAF1/VprBP ubiquitin
ligase261,400, which targets the protein to the Roc1-Cul4/DDB1 E3 complex400. However,
merlin also functions upstream of DCAF1 as a negative regulator of the ligase in the
nucleus by inhibiting its ubiquitinating activity261. By using pull-down and
coimmunoprecipitation assays, we confirmed the interaction between merlin and DCAF1,
and mapped the binding region to residues 100-314 (II, Fig.5). Some conflicting results
about the effect of C-terminal S518 merlin phosphorylation on the DCAF1 interaction
have been presented, as the association was shown to be S518 phosphorylation
independent in one study400, whereas another report demonstrated that only nuclear,
closed, unphosphorylated S518A merlin associates efficiently with DCAF1261. This could
reflect differences in merlin function in different subcellular compartments. Although we
did not detect any direct effect of S518 mutations on DCAF1 binding in our pull-down
analysis (II, Fig.5a), the results from the immunoprecipitates of soluble cellular fractions
indicate that merlin phosphorylated on both S518 and S10 would be most susceptible for
the interaction (II, Fig.5b). Li et al.261 proposed that a post-translational modification in the
nucleus could promote the interaction between merlin and DCAF1, and our results
suggest that S10 phosphorylation could represent such a mechanism.
Many tumor types harbor mutations of various components of the PI3K/Akt pathway
leading to deregulated PI3K signaling and increased Akt activity376,377. Activation of the
anti-apoptotic PI3K/Akt pathway could represent a way to inactivate merlin function in
tumors which lack NF2 mutations. Merlin is widely expressed despite the restricted
spectrum of NF2-associated tumors. However, mutations and loss of merlin expression
has been reported in also other tumor types than those associated with NF256,108-113 and
heterozygous Nf2+/- mice develop a wide range of malignant tumors, suggesting that
merlin has a broader role in cancer development66. Expression of merlin is reduced in at
least malignant gliomas424, which also show activation of the PI3K signaling pathway425.
Akt pathway hyperactivation, a common feature of many malignant neoplasias, may
result in S10 dependent degradation of merlin, and thus increased proliferation.
3. Interplay between merlin phosphorylation sites (I, II)
S518 phosphorylation through PKA and PAK regulates the activity of merlin. To extend
our findings on the interaction between PKA signaling and merlin, the interplay between
the two phosphorylation sites was investigated. We determined whether the newly
identified phosphorylation site S10 affects S518 phosphorylation, and hence merlin’s
growth inhibitory effect, by performing electrophoresis mobility shift assays with S10
mutant molecules and by analyzing their C-terminal phosphorylation status by a phospho-
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S518 specific antibody. The triplet electrophoretic migration pattern of merlin was present
in S10A and S10D constructs (I, Fig.2a) indicating that both molecules are S518
phosphorylated. This was further confirmed with the phospho-S518 antibody, which
detected both S10A and S10D merlin (I, Fig.2b). The phosphomimetic S518D mutant
localizes predominantly to membrane protrusions347 and is present at the most peripheral
regions of lamellipodia and microspikes in rat Schwann cells426. A similar localization was
detected when WT and S10 mutant expressing cells were stained for phospho-S518,
where S518 phosphorylated merlin was present in shorter cellular protrusions, but absent
from long extensions (I, Fig.2c). Only a subset of merlin molecules at specific membrane
domains were S518 phosphorylated, possibly reflecting the presence of active kinases at
these restricted areas of membrane remodeling. Since S10A and S10D mutations did not
directly affect the localization or amount of the S518 phosphorylated protein, we conclude
that the N-terminal phosphorylation of merlin is at least partly a separate event regulated
independently of C-terminal phosphorylation. It is, however, possible that the S518
phosphorylation detected in our assays is mediated through PAK, and we can therefore
not exclude the possibility that the S10 phosphorylation state would regulate PKA-
mediated phosphorylation of S518.
By altering the conformation of merlin, phosphorylation has been implicated in
modulating merlin interactions with its binding partners. Although PKA mediated
phosphorylation of S518 enhances merlin-ezrin heterodimerization346, phosphorylation of
S10 did not increase binding to ezrin in our pull-down analysis (I, Fig.2d). These results
suggest that N-terminal S10 phosphorylation does not modulate the conformation of
merlin in a similar way as S518 phosphorylation. Thus, phosphorylation of the N- and C-
terminal sites is likely to regulate distinct merlin functions. As S10 is located in the region
outside of the FERM-domain it could be available for phosphorylation also in the closed
conformation of merlin. To study if S10 phosphorylation is affected by the S518 state,
immunoprecipitated full-length S518A and S518D mutants were phosphorylated in vitro
by Akt. As the proteins were produced in mammalian cells, they should restore the
structure reflecting their true conformation. In this assay, S518D merlin showed enhanced
incorporation of phosphate compared to WT, whereas S518A merlin was less
phosphorylated on S10 (II, Fig.4b). Thus, phosphorylation of S518 enhances S10
phosphorylation, probably by rendering merlin in a more open conformation.
Both PKA phosphorylation sites, S10 and S518, function as substrate residues for
also other kinases, and S10 serves as a phosphorylation site for both PKA and Akt.
Therefore, the regulation of phosphorylation needs to be both spatially and consecutively
tightly controlled. Different extracellular stimuli at distinct intracellular localizations seem
to trigger phosphorylation of S518359. The phosphorylation status of merlin is probably
also compartmentalized, as only membrane targeted constitutively active Akt was able to
induce specific and efficient phosphorylation leading to merlin degradation. To better
understand the biological significance of N-terminal phosphorylation, we addressed the
link between PKA- and Akt-catalyzed S10 merlin phosphorylation. The experiments
demonstrated that the Akt-induced merlin degradation is not PKA-dependent, as merlin
was degraded also in the presence of PKA inhibitors. However, coactivation of Akt and
PKA had an additive effect on the degradation (II, Fig.4a). It is therefore possible that also
N-terminal PKA phosphorylation would lead to degradation of the protein if induced at
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high levels. In accordance, PKA has been suggested to regulate the stability of merlin.
Nf2 is post-transcriptionally lost in schwannomas from TEC3KO mice with increased PKA
activity but lacking Akt activation372, indicating that also enhanced PKA signaling leads to
merlin downregulation.
Figure 13. Model for post-translational merlin inactivation.
Based on our findings we propose a model for post-translational merlin inactivation
(Fig.13). When merlin inhibits proliferation, it exists in a closed conformation.
Phosphorylation at S518 in response to either PAK or PKA leads to an open molecule
where N-terminal S10 phosphorylation by Akt or PKA is enhanced. Merlin phosphorylated
at both the N- and C-terminal residues binds DCAF1 or another ubiquitin ligase, leading
to merlin degradation through the proteasomal cascade. This way merlin’s tumor
suppressive activity is lost.
Although Akt-mediated phosphorylation of T230 and S315 was not detected in our
assays, the effect of T230 and S315 mutations on S518 phosphorylation was analyzed to
understand the previously described effects of these mutants. Our assays showed that
S518 phosphorylation was abolished in the double mutant T230A+S315A (II, Fig.4c).
T230 and S315 reside at the end of the FERM-domain in the region required for N-
terminal folding. The side chain of S315 in the N-terminal α-helical segment makes a
hydrogen bond with E317 that connects to subdomain F1, and the patient mutation
S315F has been predicted to destabilize the α-helical segment leading to disrupted N-
terminal folding230. As the N-terminal fold is essential for the closed conformation, the
S315A mutation probably disrupts the intramolecular head-to-tail association of merlin,
and T230 and S315 mutants are likely to have perturbed conformations where S518 can
not be phosphorylated. Some of the effects reported for T230A+S315A mutants, such as
their reduced cell proliferation, decreased motility, and increased apoptosis329,349 might
therefore be a consequence of decreased C-terminal phosphorylation, rather than a
direct impact of the phosphorylation of these sites on merlin function.
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4. The importance of C-terminus for merlin properties (III)
Not much information is available on the functional domains of merlin. Especially the C-
terminal part remains poorly characterized, although several patient mutations have been
identified in this domain. As the C-terminus of merlin is the most divergent region from
oncogenic ezrin, it is likely that proper merlin function and inhibition of proliferation
requires an intact C-terminal region. The C-terminus of various merlin species shows
extensive sequence variability, except for a C-terminal α-helical structure, which is
evolutionally conserved (Fig.14)58. Especially the motif of residues E545-I546-E547 are
highly homologous among different merlin species, but not conserved in the ERMs (III,
Fig.4a), highlighting the importance of this region for merlin function. The isoleucine
residue at position 546 in the merlin proteins is replaced by a leucine in the
corresponding position in all ERM proteins. Interestingly, also a patient mutation
substituting glutamic acid for lysine at codon 547 of this motif has been described427, and
it represents one of the most C-terminal NF2 missense mutations reported so far.
Figure 14. Schematic model of merlin isoform 1 C-terminus. The model is based on
moesin structure and merlin predictions (combined from Pearson et al. 2000150 and
Golovnina et al. 200558). Alpha-helices are indicated with helical structures, and numbers
indicate amino acids. The C-ERMAD unique for isoform 1 is marked in purple, the
conserved α-helix is marked in orange, and the evolutionally conserved region of
residues E545-E547 is marked in red.
By characterizing C-terminally deleted constructs we might gain insight to which
regions are needed for different merlin functions. Therefore, we created truncation
variants which produce proteins that end between residues 518-587 in exons 14, 15, and
17. To characterize the conserved domain of residues E545-E547, we also generated
missense mutations that disrupt the motif and a mutant mimicking the patient mutation
previously described. Analysis of patient missense mutations can provide valuable
information about merlin function, as they should affect critical parts of the protein and are
expected to designate important regions. Several of the truncations that we used in this
study are similar to those detected in NF2 patients, such as Thr512fsX270,
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Gln536X70,75,428, and Glu547fsX270. These truncated merlin proteins often result in
functionally inactive, unstable proteins318,399,429,430. We could, however, detect expression
of a merlin variant corresponding to residues 1-548283 in a patient tumor sample (III,
Fig.1d), demonstrating that C-terminally deleted proteins can be expressed in vivo. Few
other studies have also shown that truncated proteins are detected in tumors430,431. Thus,
the abnormal function of these proteins in some of the tumors apparently causes
tumorigenesis, rather than the complete loss of merlin.
The C-terminus of merlin contains the well-characterized phosphorylation site S518,
known to regulate merlin function. As the triplet electrophoretic migration pattern of merlin
is believed to reflect differentially phosphorylated forms of the molecule247,345,346, this
assay was used to analyze the C-terminally truncated constructs. Full-length merlin
isoform 1 migrates as a triplet in SDS-PAGE, but isoform 2 containing unique C-terminal
residues and the shorter truncation constructs, migrated as single forms in our assays (III,
Fig.6a). Interestingly, merlin 1-587 displayed all three migrating species similarly to
isoform 1. To determine whether S518 phosphorylation is altered in some of the C-
terminal mutants, the constructs were detected with the phospho-S518 antibody. The
migration patterns did not correspond to the S518 phosphorylation status of the
constructs, as isoform 2 and all the truncation mutants were S518 phosphorylated
similarly to isoform 1 (III, Fig.6b). Thus, the extreme C-terminus is not directly required for
S518 phosphorylation. It has previously been suggested that isoform 2 and C-terminally
truncated constructs would have reduced PAK2-mediated phosphorylation of S518354, but
as PKA is able to phosphorylate at least isoform 2346, the observed S518 phosphorylation
in our assays could be PKA mediated. The migration pattern of merlin 1-587 indicates
that the region of amino acids 580-587 is required for the formation of the slowly
migrating band, as these residues are not present in isoform 2 or the shorter constructs
that migrate as single bands (III, Fig.6c). As mutation of all potential phosphorylation sites
in this region did not change the electrophoretic mobility of merlin (III, Fig.6d), it is unlikely
that the migration pattern observed is a direct consequence of C-terminal
phosphorylation. The different migration patterns of S518 phosphorylated and
unphosphorylated merlin molecules may reflect changes in the protein resulting from
phosphorylation rather than the S518 status. They could represent conformational
differences that depend on intramolecular associations or other post-translational
modifications, as intramolecular contacts affecting the structure can lead to differences in
migration rates although SDS-PAGE electrophoretic migration assays are used on
denaturated proteins432. The shorter C-terminally truncated molecules, and isoform 2
lacking the regulational sites between residues 580-587, do not adopt the native three-
dimensional conformation of full-length merlin isoform 1, and may therefore display
altered electrophoretic mobilities.
Merlin undergoes conformational regulation and its ability to form intramolecular
associations is believed to play an important functional role, as many of merlin’s
interactions with other molecules depend on its conformation. Although the last 10
residues of merlin are required for the association with the N-ERMAD, they are not
sufficient for the interaction, suggesting that the closed conformation involves interplay
between several different regions273. We determined the effect of C-terminal residues for
merlin folding with a pull-down analysis where constructs with different C-termini were
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allowed to interact with N-terminal fragments of merlin. The results showed that C-
terminal truncations affect the intramolecular associations in varying degrees. Merlin
isoform 2, 1-547, and E545K+E547K displayed increased binding in the assay (III,
Fig.5c), suggesting that these constructs contain a C-terminal fold where the binding sites
for the N-terminus are more accessible. Interestingly, although the E545K+E547K
mutations do not locate within the region described as critical for N- to C-terminal
folding317, the mutations still impaired the intramolecular association of merlin allowing N-
terminal binding. Thus, the last C-terminal helix in exon 17 is not the only determining
factor for the intramolecular association. Isoleucine 546 is homologous to moesin L529,
which is located at the end of the first C-terminal helix with other hydrophobic residues,
contacting subdomain F258,150. Our results indicate that a similar interaction is present
also in merlin, where the C-terminal helix participates in contacts with the N-terminal part
of the protein, this way regulating conformation. According to these results, and
supported by a recent FRET study260, merlin forms complex intramolecular associations
that require several C-terminal regions but are not S518 phosphorylation dependent.
5. Merlin-induced morphogenic changes (I, III)
Merlin functions as a linker between the membrane and cytoskeleton thus regulating cell
morphology. The morphogenic properties of merlin may play a role in its tumor
suppressor mechanism since both patient-derived schwannoma and meningioma cells
display cytoskeletal abnormalities138-141. However, it is unclear how these different merlin
functions are linked, and why both merlin overexpression and deficiency results in
cytoskeletal defects. We therefore further analyzed merlin’s morphogenic activity.
Not only the N-terminal S10 (I, Fig.2c and Fig.3), but also the C-terminal S518 has
been implicated in the regulation of merlin’s morphogenic properties350,426. In addition, the
C-terminus of ezrin has been reported to contain determinants for a cell-extension
activity195. To analyze the effect of merlin C-terminus on the morphogenic activity, and to
define the essential region, several C-terminally truncated merlin constructs and the
E547K and E545K+E547K missense mutants were expressed in various cell types. As
reported before, expression of merlin resulted in changes in cell morphology in all cell
types examined (III, Fig.2). Interestingly, the phenotypic alterations induced by merlin
isoform 2 were more pronounced than those observed with full-length isoform 1. Thus,
isoform 2 seems to have a more prominent role in modulating cytoskeletal processes.
Also some of the truncation constructs induced a significant increase in cellular
extensions, but the effect was dependent on the site of truncation. Besides isoform 2,
especially merlin 1-587, 1-547, and E545K+E547K caused major changes in morphology
by increasing both the total extension length and amount of extensions (III, Fig.2, Fig.4b,
and Table 1). Merlin 1-547 induced the most drastic phenotype with long, thin cellular
processes, similar to the previously described merlin construct 1-559259. Merlin has been
shown to promote the elongation of Schwann cell processes, and seems to stabilize the
bipolar morphology of these cells433. Expression of the 1-547 construct completely
disrupted the normal Schwann cell morphology, and the protrusion phenotype with
extremely long extensions resembled that of Schwann cells from NF2 patients139. Based
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on our results with C-terminally truncated molecules, we conclude that an internal
sequence determinant for the cell-extension activity exists in the C-terminal region of
merlin between residues 538-568. As expression of full-length merlin E545K+E547K was
sufficient to induce the formation of long protrusions, the motif of E545-E547 is essential
for merlin’s morphogenic activity.
The closed conformation of merlin isoform 1 seems to partially suppress the
morphogenic activity of the C-terminal domain in the full-length molecule, similarly to
ezrin. The more unfolded conformation of merlin isoform 2 and some of the mutants could
make the proteins more prone to molecular interactions, this way increasing their
cytoskeletal effect and leading to the observed changes in cell morphology. Since the
morphogenic effect was not linearly dependent on the length of the construct, the C-
terminus could also contain a silencer domain that prevents complete morphogenic
activity of the full-length protein. The silencer domain could be deleted in some of the
truncation constructs allowing a functional site inside the molecule to be unmasked, thus
permitting merlin to interact with other molecules and influencing cell morphology.
The biological significance of merlin’s cell-extension activity has not been elucidated,
but morphological changes are essential in many physiological situations. Extension
formation is required when neurons grow their axons, dendrites, and dendritic spines in
the CNS during neurogenesis. Merlin and ezrin are widely expressed and
developmentally regulated in the CNS, suggesting that the proteins could have a
regulatory role in neurogenesis237. Both the ERMs and merlin have also been linked to
neuronal morphogenesis. ERMs are present in neuronal growth cones, and they have a
function in the outgrowth of axons176. Merlin facilitates neurite outgrowth through its
interaction with paxillin in neuroblastoma cells434, but inhibits neurite formation in
differentiated neurons435 and in neuroblastoma if deficient in paxillin binding434. Thus, the
merlin-induced cytoskeletal rearrangements and morphogenic changes might play a role
in the formation of neuronal extensions.
To better understand the mechanism of merlin-induced extension formation, we
analyzed the process by live cell imaging. Merlin isoform 2 was present in the imaged
Nf2-/- MEFs in the lamellipodia at the leading edge but also as a gradient from the tails in
the rear towards the center (III, Fig.3c and Fig.3d). Live cell imaging demonstrated that
the merlin-induced cell extension phenotype is a dynamic process, where the protrusions
are not actively formed through filopodia elongation, but rather their retraction during cell
movement is altered (III, Fig.3b). The long protrusions are formed as a result of impaired
release of adhesion points when the cell continues its movement to the opposite
direction, consequently forming an actin and tubulin-containing tail (III, Fig.3a) behind the
cell at the lagging edge. Adhesion disassembly is required for tail retraction133, and merlin
localizes to cell-substrate contacts and associates with focal adhesion components such
as FAK436, paxillin277, and β-integrin264. Merlin might control cell extension formation by
connecting focal adhesion proteins to the actin cytoskeleton, and this way be essential for
the regulation of morphological changes. Merlin, β1-integrin, ErbB2 receptors, paxillin,
Cdc42, and PAK are all enriched at the distal tips of Schwann cell processes359, and the
interaction between merlin and paxillin is involved in regulating actin-based morphological
changes in these cells277. Thus, the morphological changes detected in our assays could
be at least partly mediated by paxillin. Several other merlin interacting proteins are
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associated with cell migration and could possibly explain the formation of the extended
tail. Retraction of the rear requires Rho and ROCK, and inhibition of RhoA leads to the
formation of an extended tail437-439, similarly to overexpressed merlin. Thus, the tail
retraction effect could be a consequence of merlin influencing the Rho signaling pathway,
possibly indirectly through the other Rho GTPases. However, also active Rac is required
for rear detachment of migrating cells, and expression of a dominant-negative Rac
mutant leads to a phenotype where the tails are stuck to the substratum440. Moreover,
active PAK1 localizes to focal complexes at the tips of membrane protrusions441,
Dictyostelium cells deficient in PAK show impaired retraction442, and merlin can
antagonize the activity of PAK by inhibiting its recruitment to focal adhesions303. Finally,
the ERM proteins have also been implicated in tail retraction and polarization443, making
ezrin yet another possible interaction partner that could be involved in merlin-induced
morphological changes. Thus, several molecular pathways could affect the formation of
merlin-induced cellular processes, and it remains to be investigated which of these
molecular interactions are essential for the activity.
6. The effect of ezrin on merlin-induced morphological changes (III)
Most cell types coexpress several ERM proteins together with merlin. The proteins
interact through heterodimerization273,274, and merlin often colocalizes with ezrin at the
plasma membrane in cultured cells (Fig.15)263. However, in cells with a poorly developed
actin cytoskeleton, overexpressed merlin replaces ezrin in filopodia and ruffling
edges263,291. The subcellular colocalization of merlin and ezrin also depends on growth
conditions in some cell types; in subconfluent U251 glioma cells the proteins colocalize,
whereas in confluent cells, where merlin presumably suppresses proliferation, they do not
distribute to the same subcellular locations273. Although merlin and ezrin often showed
equivalent subcellular distribution at the cell membrane in our stainings, there was no
colocalization in the long merlin-induced protrusions observed in Nf2-/- MEFs (III, Fig.3d
and Fig.5a), suggesting that the proteins might not have cooperative functions in the
formation of these structures.
Both N- and C-terminal truncations of ezrin increase the ratio of cell extensions,
whereas the full-length molecule forms a self-complex that masks the availability of the
domains needed for protrusions formation195. Thus, merlin-induced regulation of cell
morphology resembles the mechanism described for ezrin, where the cell extension
activity of the full-length protein is reduced, but deletion of residues at either end of the
protein releases the extension phenotype. However, in contrast to ezrin, also full-length
merlin isoform 1 induces the formation of extensions, indicating that the effect on cell
morphology of these homologous proteins is not identical. Since ezrin also causes
morphological changes and the phenotypic effect of merlin may be mediated through
ezrin, we investigated whether the merlin phenotype is ezrin dependent by expressing the
truncation constructs in ezrin-deficient MEFs. The merlin truncations failed to induce
similar protrusion formation in ezrin-/- MEFs as in cells containing endogenous ezrin, and
only the full-length merlin isoforms triggered a cell-extension phenotype (III, Fig.5b). The
reduced effect of the truncated constructs in protrusion formation shows that the C-
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terminally regulated extension formation is affected by the interplay with ezrin. However, it
should be noted that these cells express also endogenous merlin, which could interfere
with the C-terminally deleted molecules.
Figure 15. Merlin and ezrin colocalize at the cell membrane. 293 HEK cells
transfected with merlin WT were stained for merlin (red) and endogenous ezrin (green).
The plot profile displays a two-dimensional graph of the intensities of pixels along the
rectangular section parallel to the protrusion. The x-axis in the graph represents the
horizontal distance through the rectangular section from the cell body toward the end of
the extension and the y-axis the vertically averaged pixel intensity. Merlin staining is
shown in red and ezrin staining in green.
To study whether this reduced ability of merlin truncations to induce morphogenic
changes would result from altered merlin-ezrin binding, a pull-down analysis with full-
length ezrin was conducted. However, the interaction between merlin and ezrin was not
affected by the truncations (III, Fig. 5c), suggesting that the reduced ability of the C-
terminal variants to form protrusions in the absence of ezrin is not a consequence of a
lack of this binding partner. Therefore, we conclude that ezrin is not required for the cell-
extension activity of full-length merlin, but influences the formation and length of merlin-
induced protrusions.
7. The effect of merlin C-terminus on growth inhibition (III)
Neither the N-terminus nor the C-terminus of human merlin is by itself sufficient for growth
suppression242, and both the F2 subdomain of the FERM-domain and the C-terminal
region of 532-579 have been defined as essential for merlin-mediated inhibition of
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Schwann cell proliferation444. To further study the effect of merlin C-terminus on growth
inhibition, two different assays were conducted. Anchorage-independent growth was
analyzed by performing a soft agar analysis, and the proliferation status of the cells was
determined by using the proliferation marker Ki-67. Interestingly, whereas the full-length
isoforms suppressed growth in both these assays, the C-terminal mutants, both the
truncation 1-547 and the missense mutant E545K+E547K, had only a minor effect on cell
proliferation and anchorage-independent growth (III, Fig.7 and Table 1). The reduced
growth inhibitory function of these constructs further defines the importance of the
conserved residues around 545-547, and confirm that an intact C-terminus is required for
the full growth inhibitory effect of human merlin. The results differ from experiments done
with D-merlin, where the essential functions of the protein reside within the FERM-
domain. In contrast to human merlin 1-547, D-merlin 1-600, with a deletion of the 35 most
C-terminal residues, functions as a gain-of-function allele, acting as an activated protein
in Drosophila249. Thus, significant functional differences in human and fly merlin seem to
exist, despite their high sequence conservation.
Table 2. Missense mutations in NF2 exon 15. Identified missense mutations in exon 15
(corresponding to residues 525-579) and their previously described cellular effects.
Mutation Protein Phenotype Reported effects References
1598A>C K533T severe NF2 Nd [445;446]
1604T>C L535P mild NF2 reduced binding to βII-spectrin, HRS, p110,EBP50, and isoform 2, decreased self-interaction,
increased solubility, impaired growth suppression,
decreased half-life, impaired effect on motility,
decreased adhesion, does not disorganize actin
cytoskeleton, increase in microspikes
[259; 267; 284;
286; 290; 318;
319; 402;
447;448]
1613A>C Q538P variable NF2 reduced binding to βII-spectrin, HRS, p110, andisoform 2, decreased self-interaction, impaired
growth suppression, does not disorganize actin
cytoskeleton, impaired effect on motility
[76; 267; 290;
319; 449]
1616T>A L539H Nd [450]
1652T>A L542H Nd [290]
1639G>A E547K neurofibroma-
perineurioma
Nd [427]
1736A>T K579M Nd [446]
Nd = not determined
Despite the fact that many of the identified patient mutations localize to the N-terminal
part of merlin73,74, also several interesting C-terminal mutations in exon 15 (corresponding
to residues 525-579) have been described. Although missense mutations are rare and
occur at a low frequency representing only 5% of all NF2 mutations (Fig.3)73, almost one
third are located in exon 15258. This implies that the region is essential for merlin function.
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The identified missense mutations and their reported effects are shown in Table 2. These
C-terminal mutations seem to cause variable clinical phenotypes, and most of them have
been described to contain reduced growth inhibitory function. Most of the characterized
disease-causing missense mutations in merlin are predicted to disrupt folding of the
protein, indicating that the overall three-dimensional structure is essential for tumor
suppressive function. For example mutations L535P and Q538P are predicted to break
the conserved C-terminal helix, which probably disturbs merlin’s function by altering the
structural properties of the C-terminus160. The importance of exon 15 and the region
around 547 is further endorsed by the identification of the missense mutation E547K.
Although the patient was not diagnosed with NF2, she had atypical hybrid neurofibroma-
perineurioma427. We speculate based on our binding assays that the functional defect
caused by this mutation is a result of a structural change in the conformation of the
protein rather than the direct consequence of a single residue substitution.
The construct that we characterized to have the most drastic effect on cell
morphology, 1-547 is tumorigenic according to our proliferation assays. This is of interest
since mutations resulting in truncations around merlin residue 547 are found in both NF2
patients and in sporadic schwannomas70,451. These patient mutations further confirm that
removing the very C-terminal residues of merlin impairs its function, leading to tumor
formation. It is also possible that some of the truncations, also found in patients, could
exert a dominant-negative effect by interfering with and possibly inactivating the function
of WT merlin. This is supported by the fact that both full-length and truncated forms of
merlin are coexpressed in some schwannomas431, and the phenotypes for truncating
mutations appear to be more severe than for whole gene deletions48. The HEI-193 cell
line, immortalized from schwannoma cells of an NF2 patient, expresses a protein
consisting of exons 1-14 followed by an altered exon 17452. This form lacking both exons
15 and 16 has been designated as merlin isoform 3 as it is detected also in normal cells
at a low level234. Isoform 3 was found to be expressed together with a mutant protein in
tumors of patients with mild manifestations of NF2453,454, and the isoform has been
proposed to retain a partial tumor suppressive activity452,453. This splice variant is also
detected in many malignant mesotheliomas113. In one study, deletion of NF2 exons 15-16
was described as the most frequent exon deletion found among NF2 patients455, further
confirming that these C-terminal exons are essential for merlin function. Thus, both the
mutational analyses and our novel data indicate that alterations in exon 15 are enough to
significantly reduce the growth inhibitory function of merlin.
8. Differences between merlin isoforms (III)
Not much information is available on the different merlin isoforms, and their functional
significance is unclear. However, evolutional conservation together with similarly
alternatively spliced mouse and human homologues suggest that the isoform 1 and 2
bear functional relevance59. The mRNA of both isoforms is present in Schwann and
meningeal cells234,274, so they could equally be involved in NF2 tumorigenesis.
Interestingly, knockout mice that express only merlin isoform 2 develop normally into
healthy adults157. Thus, isoform 2 is able to rescue the phenotype resulting from lack of
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isoform 1, indicating that the isoforms have redundant functions during at least
embryogenesis and growth.
Overexpression of merlin isoform 1 impairs cell motility, but such effects are not
observed with isoform 2286. Similarly, merlin isoform 1, but not isoform 2, reverses the
cytoskeletal defects of Nf2-deficient schwannoma cells283. Merlin isoform 2 induces the
formation of long cell protrusions in our studies and associates more efficiently with F-
actin than isoform 1272. The actin binding properties of the two merlin isoforms are
probably different because the N-terminal ABS is not available in the closed conformation
of isoform 1193. The different affinities for actin could explain the more pronounced
morphogenic effects of isoform 2, as stronger interaction of isoform 2 with cytoskeletal
components might cause increased focal adhesion stability, this way affecting
detachment of protrusions. The stronger regulatory function in protrusion formation of
isoform 2 may also partly explain why it is not able to reverse the morphology of merlin-
deficient schwannoma.
Inactivating mutations in the NF2 gene occur in the first 15 coding exons, but have not
been reported in the last exons 16 and 17 that distinguish the two isoforms from each
other73,74. The absence of tumor producing mutations in these exons has led to the belief
that disruption of the proteins alternative C-termini would not be sufficient to eliminate
merlin’s tumor suppressor function456, although C-terminally truncated molecules have
been described as incapable of influencing cell proliferation. The ability of merlin to
function as a negative growth regulator has been suggested to be dependent on its
intramolecular association242. The distinct C-terminus of isoform 2 is predicted to result in
a molecule with an open conformation, and also our studies demonstrated that isoform 2
exists in a structure that is more open than the conformation of isoform 1 (III, Fig.5c).
However, according to our results, both full-length merlin isoforms 1 and 2 are equally
able to suppress Ras-induced anchorage-independent cell growth and to decrease cell
proliferation (III, Fig.7), regardless of their conformation. As isoform 2 retains growth
inhibitory properties, full intramolecular association between the N- and C-terminal
domains is not required to negatively regulate cell proliferation. This is in accordance with
a recent study of Schwann cell proliferation444. However, further studies are needed to
explain the controversial results of isoform 2 on growth inhibition in some experimental
systems242.
To conclude, the merlin isoforms have different functions in regulating cytoskeletal
changes, which seem to affect both cell morphology and migration. However, these
merlin functions are probably distinct from the growth inhibitory activity, as isoform 2 with
high cell extension activity is able to inhibit proliferation in our assays (III, Table 1).
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CONCLUSIONS AND FUTURE PERSPECTIVES
While the hereditary cancer syndromes make up only a small fraction of the overall
cancer burden, the study of these disorders is important as it not only provides insights
into the regulatory molecular pathways of the syndromes, but also elucidates essential
mechanisms in sporadic tumorigenesis. Merlin seems to be a key growth regulator also in
nonhereditary nervous system malignancies, as NF2 gene inactivation is observed in a
large fraction of sporadic schwannomas and meningiomas. Although NF2 is a rare
disease, sporadic schwannomas and meningiomas are common, and population studies
suggest that up to 1:300 of individuals will develop a tumor with an underlying sporadic
NF2 mutation during their lifetime457. Defining merlin’s normal physiological function in
detail and understanding the molecular mechanisms behind NF2-related tumorigenesis is
therefore needed to improve prevention and treatment of both the hereditary and
sporadic tumors.
This work has resulted in several interesting observations on the biology of the NF2
tumor suppressor protein merlin. We hypothesized that the regions that are unique to
merlin may, in part, be responsible for its specificity as a tumor suppressor. As the C-
terminus of merlin is most divergent from ERM proteins, it is likely that proper merlin
function requires an intact C-terminus. We therefore studied the role of the most C-
terminal regions on merlin’s cellular and molecular properties, such as proliferation,
cytoskeletal organization, phosphorylation, and intramolecular associations. The motif of
amino acids 545-547 is conserved among the merlin proteins, and mutations affecting
these residues have been speculated to affect protein function58. According to our
studies, the conserved C-terminal helix (amino acids 510-553), and in particularly the
region between residues 538-568, functions as a regulatory domain of merlin-induced cell
extension formation, which is a consequence of impaired detachment of adhesive
structures. We also obtained evidence that the conformational regulation of merlin is
highly more complex than previously thought. Truncation at 547 or substitution of the
glutamic acid residues E545 and E547 disrupts the conserved helix and alters the
conformation of the C-terminus sufficiently to eliminate productive intramolecular
association. Thus, merlin forms more intricate conformations than just the “open” and
“closed” states, and these structures require C-terminal residues other than exon 17.
Although the significance of isoform 2 still remains largely unknown, our study has
given insights into its functions. It has been assumed that the closed state of merlin is the
functionally active tumor suppressive molecule. Our results show that despite the different
morphogenic effects of the two isoforms, they possess equal growth inhibitory activities.
This implies that the region distinguishing the two isoforms is not critical for merlin’s tumor
suppressive activity, as both C-termini are capable of mediating this function. The open
structure is probably not as such sufficient to disrupt merlin’s growth inhibitory function,
but more complex conformational regulation is likely to be essential for this activity. It is of
interest that no mutations have been identified in the last exons 16 and 17 that differ
between the two isoforms. It is possible that such mutations would cause embryonic
lethality, and would hence not be detected. Alternatively, mutations in the last exons are
not harmful if they do not disturb the tumor suppressive activity of merlin, and do not
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therefore cause tumorigenesis. To understand the lack of mutations in the last exons it
would be of interest to sequence the NF2 gene from healthy individuals to analyze
whether such mutations can be detected.
The results in this study show that overlapping but distinct C-terminal sequences of
merlin mediate functions related to growth suppression, cellular morphology and control
of molecular interactions (III, Table 1). The C-terminal α-helix, and especially the
conserved residues of 545-547 were found particularly critical for all merlin functions
analyzed. The importance of the region around 547 is further supported by the high
conservation around the motif and identification of several pathogenic mutations within
these residues that either truncate or cause missense mutations in the molecule.
Although the region regulating protrusion formation overlaps with residues required for
the tumor suppressive function, the morphogenic activity of merlin does not appear to be
directly linked to growth inhibition. To further clarify whether the morphogenic properties
are associated with contact inhibition, additional investigations of the molecular
interactions essential for merlin’s morphogenic activity will be required.
The NF2-related intracranial tumors are clinically severe due to their location despite
their benign and slow-growing features. Surgery and radiosurgery, the current treatments,
target only single tumors and have associated adverse effects and major risks. As no
other effective treatments are currently available, molecular therapies are urgently
needed457,458. Strategies to identify effective medical therapies for NF2 require the
delineation of merlin’s molecular pathways, and analysis of the signaling events that
mediate merlin activation could provide important molecular targets for future therapeutic
drug design. Post-translational modification via phosphorylation is an important
mechanism in the regulation of merlin function. The studies in this thesis identified a
previously uncharacterized merlin phosphorylation site by confirming S10 as a substrate
residue for both PKA and Akt. The identified phosphorylation site, S10, represents a
novel Akt substrate recognition motif, R-X-S10, with an arginine at -2 position.
Furthermore, PKC was shown to function as a merlin phosphorylating kinase, although
the substrate residue was not mapped further than to the N-terminal region.
Phosphorylation of S10 leads to modulation of the actin filament organization and cell
morphology, indicating that normal regulation of the S10 phosphorylation state is critical
for merlin’s cytoskeletal function. Our study also provides further evidence on the
connection between merlin function and PI3K/Akt signaling, and implicates an important
role for Akt in the regulation of merlin stability. Based on the work presented here, we
propose that an unattributed consequence of Akt pathway overactivation in different
malignancies is increased degradation of the tumor suppressor merlin. We postulate that
temporal transient phosphorylation of S10 regulates the cytoskeletal functions of merlin,
whereas constitutive phosphorylation in malignant cells leads to merlin degradation.
However, the cross-talk and complexity between Akt, PKA, and PAK signaling makes
evaluation of the biological impact of merlin phosphorylation challenging and demands
further analysis.
Our findings are important since alternative mechanisms to mutation for merlin
inactivation in NF2-associated tumors might exist. Some tumors lack detectable NF2
mutations, but lose merlin expression93 despite expression of NF2 transcripts410.
Approximately one-third of schwannomas have genetic evidence for inactivation of only
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one of the NF2 alleles, and in about 10% of tumors genetic NF2 alterations have not
been detected at all93. Thus, many tumors may carry at least one intact copy of the NF2
gene, whose product must be inactivated for schwannoma development. These
observations implicate the involvement of merlin degradation in tumor development. NF2
tumorigenesis might therefore involve alterations at many different levels, including post-
translational modifications and protein turnover. Increased phosphorylation in tumors with
hyperactivated Akt, such as in some VSs383, could result in merlin degradation and
subsequent inactivation of its growth inhibitory function. Phosphorylation by Akt could
also function as a mechanism to inactivate merlin in normal benign cells during growth
promoting conditions. It remains to be investigated in which situations the Akt mediated
degradation of merlin occur, and if S10 phosphorylation plays a role in the normal
functional regulation of merlin, or whether it is just a consequence of Akt overactivation in
neoplasia.
Several compounds targeting signal transduction and kinases are used in treatment of
human cancers, and inhibitors of the PI3K/Akt pathway are already in clinical trials360. As
merlin is phosphorylated by multiple kinases, many signaling events are potential targets
and several possible levels for NF2 therapeutic intervention exist457. Inhibitors of the
PI3K-Akt pathway could potentially be used in restoring merlin function at least in tumors
without NF2 mutations. OSU-03012, a PDK1 inhibitor, has recently been investigated as
chemotherapeutic in preclinical studies for schwannomas, and this Akt pathway targeting
compound suppressed primary human VS cell proliferation in vitro and induced their
apoptosis459. It remains to be seen whether Akt inhibitors, among to their other effects,
can restore the function of merlin in tumors where functional protein remains expressed.
Also compounds effective in delaying proteasomal degradation could be tested, as
modulation of this pathway should increase merlin’s half-life by reducing its degradation
in tumors with hyperactivated Akt or PKA. Several proteasome inhibitors, which block
proliferation and induce apoptosis, have undergone clinical trials as anti-tumor agents460.
Inactivation of some of these pathways could hopefully reduce tumor cell proliferation and
have therapeutic potential for patients suffering from tumors associated with NF2.
The studies in this thesis have expanded our knowledge on the functional regulation
of merlin. Our findings provide clues on the molecular mechanisms involved in the
tumorigenetic events of NF2, by characterizing PKA and Akt mediated phosphorylation of
merlin. These studies are highly relevant for understanding the normal function of merlin
and will hopefully help in the ultimate goal of developing effective treatments for both
NF2-associated and sporadic tumors.
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SUMMARY
The main results of this study are:
(1) Merlin contains two PKA phosphorylation sites, serine 10 at the N-terminal
domain and serine 518 at the C-terminus. Phosphorylation of serine 10
regulates merlin-induced cell morphology and affects actin filament
organization and stability.
(2) The N-terminal serine 10 in merlin is also a substrate for the oncogenic
kinase Akt. Merlin and Akt interact through an N-terminal Akt binding site,
but the interaction is not regulated by S10 phosphorylation.
(3) Akt phosphorylated merlin is degraded through a proteasome-dependent
pathway. Serine 10 phosphorylation could represent a non-genetically
modified, post-translational mechanism of NF2 inactivation.
(4) Overlapping C-terminal regions of merlin mediate functions related to
growth suppression, cytoskeletal organization, and control of molecular
interactions.
(5) Merlin’s morphogenic properties are regulated by the C-terminus,
particularly residues 538-568. C-terminally truncated proteins induce an
increase in membrane-associated cellular projections, which are formed as
a result of impaired tail retraction during cell movement.
(6) Both merlin full-length isoforms are able to inhibit cell proliferation and
anchorage-independent growth, whereas C-terminally mutated merlin
constructs show a decrease in growth suppression.
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